

AMENDMENTS TO THE SPECIFICATION

Applicants submit herewith a clean version and a marked up version of the specification under 37 C.F.R. §1.125. In particular, Applicants have amended the specification to remove the references to a deposit with the ATCC.



CLEAN VERSION OF SPECIFICATION

BETA-CAP73 CONTROL OF NORMAL AND ABNORMAL CELL MIGRATION

5 **Related Applications**

This application claims priority to U.S. Provisional Application No. 60/170,182, filed on December 10, 1999, and U.S. Utility Application No. 09/733,818, filed on December 8, 2000 (Attorney Docket No. TUI-001), the contents of each are incorporated herein in their entirety by this reference.

10

Government Support

This invention was made with government support under GM55110 awarded by the National Institutes of Health. The government has certain rights in the invention.

15 **Background of the Invention**

Many eukaryotic cells necessarily possess the ability to move within their environment in response to certain stimuli (e.g. endothelial cells in response to injury, macrophages during immune response). This property of motility is facilitated by coordinated and dynamic modifications to the structure of the cytoskeleton, resulting in net

20

movement. A major cytoskeletal component of motile eukaryotic cells are actin complexes, whose filamentous structure throughout the cell is complex and highly variable. Numerous isoforms of eukaryotic actin have been identified, many of which are found distributed to specific areas of the cell and its cytoskeleton. The ability to disassemble and reassemble actin polymers in a controlled and orderly fashion is central to proper cellular motility.

25

Polymerized actin exists in equilibrium with the monomeric form. The equilibrium constant for the polymerization and depolymerization reactions of actin can be altered by the presence of actin-binding proteins (ABPs). These proteins play an important role in a cell's ability to control cytoskeletal rearrangements, and hence, promote effective cell motility.

30

Many vital functions are served through the ability of some cells to migrate, including response and repair or tissue damage.

Summary of the Invention

The present invention is based, at least in part, on the discovery of a novel β -actin specific binding protein and its family members, referred to herein as "beta-cap73" or

35

"BETA-CAP73" or " β cap73" or " β CAP73" or "BCAP73" or "bcap73" nucleic acid and protein molecules. The bcap73 molecules of the present invention are useful as modulating agents to regulate a variety of cellular processes, including but not limited to cell motility,

directed migration, subcellular distribution of β -actin, response to injury, and changes in cellular morphology. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding bcap73 proteins or biologically active portions thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection of
5 bcap73-encoding nucleic acids.

In one embodiment, a bcap73 nucleic acid molecule of the invention is at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 83%, 85%, 90%, 95%, 98%, or more identical to the nucleotide sequence (*e.g.*, to the entire length of the nucleotide sequence) shown in SEQ ID NO:1 or 3, or a complement thereof.

10 In a preferred embodiment, the isolated nucleic acid molecule includes the nucleotide sequence shown SEQ ID NO: 1 or 3, or a complement thereof. In another embodiment, the nucleic acid molecule includes SEQ ID NO: 3 and nucleotides 392-4597 of SEQ ID NO: 1. In another preferred embodiment, the nucleic acid molecule consists of the nucleotide sequence shown in SEQ ID NO: 1 or 3. In another preferred embodiment, the
15 nucleic acid molecule includes a fragment of at least 1911 nucleotides (*e.g.*, 1911 contiguous nucleotides) of the nucleotide sequence of SEQ ID NO: 1 or 3, or a complement thereof.

In another embodiment, a bcap73 nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence sufficiently identical to the
20 amino acid sequence of SEQ ID NO: 2. In a preferred embodiment, a bcap73 nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 83%, 85%, 90%, 95%, 98% or more identical to the entire length of the amino acid sequence of SEQ ID NO: 2.

In another preferred embodiment, an isolated nucleic acid molecule encodes the
25 amino acid sequence of bovine or human or another vertebrate bcap73. In yet another preferred embodiment, the nucleic acid molecule includes a nucleotide sequence encoding a protein having the amino acid sequence of SEQ ID NO: 2. In yet another preferred embodiment, the nucleic acid molecule is at least 1911 nucleotides in length. In a further preferred embodiment, the nucleic acid molecule is at least 1911 nucleotides in length and
30 encodes a protein having a bcap73 activity (as described herein).

Another embodiment of the invention features nucleic acid molecules, preferably bcap73 nucleic acid molecules, which specifically detect bcap73 nucleic acid molecules relative to nucleic acid molecules encoding non-bcap73 proteins. For example, in one
35 embodiment, such a nucleic acid molecule is at least 1911, 1911-2000, 2000-2250, 2250-2500, 2500-2750, 2750-3000, 3000-3250, 3250-3500, 3500-3750, 3750-4000, 4000-4250, 4250-4500, 4500-4736 or more nucleotides in length and hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence shown in SEQ ID NO: 1, or a complement thereof. The lengths of nucleic acid molecules of this invention can

be within a range using any one of the aforementioned numbers as the upper or lower limit of the range. For example, the nucleic acid molecules can be of a length between at least 1911 and 3000 nucleotides in length.

In preferred embodiments, the nucleic acid molecules are at least 15 (*e.g.*,
5 contiguous) nucleotides in length and hybridize under stringent conditions to nucleotides 1-357, 2268-3135, 4227-4736, of SEQ ID NO: 1. In other preferred embodiments, the nucleic acid molecules comprise nucleotides 1-357, 2268-3135, 4227-47326, of SEQ ID NO: 1. In other preferred embodiments, the nucleic acid molecules consist of nucleotides 1-357, 2268-3135, 4227-4736, of SEQ ID NO: 1.

10 In other preferred embodiments, the nucleic acid molecule encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO: 1 or 3 under stringent conditions.

Another embodiment of the invention provides an isolated nucleic acid molecule
15 which is antisense to a bcap73 nucleic acid molecule, *e.g.*, the coding strand of a bcap73 nucleic acid molecule.

Another aspect of the invention provides a vector comprising a bcap73 nucleic acid molecule. In certain embodiments, the vector is a recombinant expression vector. In another embodiment, the invention provides a host cell containing a vector of the invention.
20 In yet another embodiment, the invention provides a host cell containing a nucleic acid molecule of the invention. The invention also provides a method for producing a protein, preferably a bcap73 protein, by culturing in a suitable medium, a host cell, *e.g.*, a mammalian host cell such as a human or a non-human mammalian cell, of the invention containing a recombinant expression vector, such that the protein is produced.

25 Another aspect of this invention features isolated or recombinant bcap73 proteins and polypeptides. In one embodiment, the isolated protein, preferably a bcap73 protein, includes at least one ankyrin repeat domain. In another embodiment, the isolated protein, preferably a bcap73 protein, includes an actin binding domain. In another embodiment, the isolated protein, preferably a bcap73 protein, includes an ezrin binding domain. In yet
30 another embodiment, the isolated protein, preferably a bcap73 protein, includes at least one ankyrin repeat domain and an actin binding domain. In a preferred embodiment, the protein, preferably a bcap73 protein, includes at least one ankyrin repeat domain and has an amino acid sequence at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more identical to the amino acid sequence of SEQ ID NO: 2. In another
35 preferred embodiment, the protein, preferably a bcap73 protein, includes an actin binding domain and has an amino acid sequence at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 83%, 85%, 90%, 95%, 98% or more identical to the amino acid sequence of SEQ ID NO: 2. In a further preferred embodiment, the protein, preferably a bcap73

protein, includes at least one actin binding domain and an ankyrin repeat domain and has an amino acid sequence at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 83%, 85%, 90%, 95%, 98% or more identical to the amino acid sequence of SEQ ID NO: 2.

5 In another preferred embodiment, the protein, preferably a bcap73 protein, includes at least one ankyrin binding domain and plays a role in cytoskeletal structure and cell motility, *e.g.*, the regulation of actin function and/or actin intracellular distribution. In yet another preferred embodiment, the protein, preferably a bcap73 protein, includes an actin binding domain and plays a role in cell motility, *e.g.*, the regulation of actin function and/or
10 the intracellular distribution of actin. In a further preferred embodiment, the protein, preferably a bcap73 protein, includes at least one ankyrin binding domain and one actin binding domain and plays a role in cell motility, *e.g.*, the regulation of actin function and/or the intracellular distribution of actin. In yet another preferred embodiment, the protein, preferably a bcap73 protein, includes at least one ankyrin binding domain and is encoded by
15 a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1 or 3. In a further embodiment, the protein, preferably a bcap73 protein, includes an actin binding domain and is encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic
20 acid molecule comprising the nucleotide sequence of SEQ ID NO: 1 or 3. In another embodiment, the protein, preferably a bcap73 protein, includes at least one ankyrin binding domain and at least one an actin binding domain and is encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1 or 3.

25 In another embodiment, the invention features fragments of the protein having the amino acid sequence of SEQ ID NO: 2, wherein the fragment comprises at least 15 amino acids (*e.g.*, contiguous amino acids) of the amino acid sequence of SEQ ID NO: 2. In another embodiment, the protein, preferably a bcap73 protein, has the amino acid sequence of SEQ ID NO: 2.

30 In another embodiment, the invention features an isolated protein, preferably a bcap73 protein, which is encoded by a nucleic acid molecule consisting of a nucleotide sequence at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 83%, 85%, 90%, 95%, 98% or more identical to a nucleotide sequence of SEQ ID NO: 1 or 3, or a complement thereof. This invention further features an isolated protein, preferably a bcap73
35 protein, which is encoded by a nucleic acid molecule consisting of a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1 or 3, or a complement thereof.

The proteins of the present invention or portions thereof, *e.g.*, biologically active portions thereof, can be operatively linked to a non-bcap73 polypeptide (*e.g.*, heterologous amino acid sequences) to form fusion proteins. The invention further features antibodies, such as monoclonal or polyclonal antibodies, that specifically bind proteins of the invention, preferably bcap73 proteins. In addition, the bcap73 proteins or biologically active portions thereof can be incorporated into pharmaceutical compositions, which optionally include pharmaceutically acceptable carriers.

In another aspect, the present invention provides a method for detecting the presence of a bcap73 nucleic acid molecule, protein or polypeptide in a biological sample by contacting the biological sample with an agent capable of detecting a bcap73 nucleic acid molecule, protein or polypeptide such that the presence of a bcap73 nucleic acid molecule, protein or polypeptide is detected in the biological sample.

In another aspect, the present invention provides a method for detecting the presence of bcap73 activity in a biological sample by contacting the biological sample with an agent capable of detecting an indicator of bcap73 activity such that the presence of bcap73 activity is detected in the biological sample.

In another aspect, the invention provides a method for modulating bcap73 activity comprising contacting a cell capable of expressing bcap73 with an agent that modulates bcap73 activity such that bcap73 activity in the cell is modulated. In one embodiment, the agent inhibits bcap73 activity. In another embodiment, the agent stimulates bcap73 activity. In one embodiment, the agent is an antibody that specifically binds to a bcap73 protein. In another embodiment, the agent modulates expression of bcap73 by modulating transcription of a bcap73 gene or translation of a bcap73 mRNA. In yet another embodiment, the agent is a nucleic acid molecule having a nucleotide sequence that is antisense to the coding strand of a bcap73 mRNA or a bcap73 gene.

In one embodiment, the methods of the present invention are used to treat a subject having a disorder characterized by aberrant or unwanted bcap73 protein or nucleic acid expression or activity by administering an agent which is a bcap73 modulator to the subject. In one embodiment, the bcap73 modulator is a bcap73 protein. In another embodiment the bcap73 modulator is a bcap73 nucleic acid molecule. In yet another embodiment, the bcap73 modulator is a peptide, peptidomimetic, or other small molecule. In a preferred embodiment, the disorder characterized by aberrant or unwanted bcap73 protein or nucleic acid expression is a disorder associated with deregulated cell motility or with aberrant intracellular distribution of actin isoforms (*e.g.* β -actin); or with inability to adequately respond to tissue damage; or with tumor-induced angiogenesis; or with cardiovascular disorders or conditions.

The present invention also provides diagnostic assays for identifying the presence or absence of a genetic alteration characterized by at least one of (i) aberrant modification or

mutation of a gene encoding a bcap73 protein; (ii) mis-regulation of the gene; and (iii) aberrant post-translational modification of a bcap73 protein, wherein a wild-type form of the gene encodes a protein with a bcap73 activity.

In another aspect the invention provides methods for identifying a compound that binds to or modulates the activity of a bcap73 protein, by providing an indicator composition comprising a bcap73 protein having bcap73 activity, contacting the indicator composition with a test compound, and determining the effect of the test compound on bcap73 activity in the indicator composition to identify a compound that modulates the activity of a bcap73 protein.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

Brief Description of the Drawings

Figure 1: A photograph of indirect immunofluorescence showing localization of bcap73 in cells that are moving into a wound (top). Also visible are contact-inhibited cells behind the wound edge which show no cortical enrichment of bcap73. Nuclear staining is background signal generated by the labelled tertiary antibody.

Figure 2: Results of two-step purification of bcap73 from bovine retinal pericytes or bovine platelets using ion-exchange chromatography. A Triton X-100 lysate (A) is enriched for bcap73 with SP-sepharose (B) followed by DEAE-sepharose (C). An decrease in contaminating proteins can be seen in the silver stained SDS-PAGE, as well as a concomitant enrichment of bcap73 which is shown in the immunoblot.

Figure 3: (A) A northern blot shows the 4.7kb mRNA of bcap73 in endothelial cells. (B) A schematic representation of the cDNA of bovine bcap73 which shows the portion of the cDNA that was originally identified from a bovine endothelial cell library, and the region that was reconstructed using 5'RACE (rapid amplification of cDNA ends). (C) Recombinant β CAP73 expression constructs are also indicated. (D) Schematic representation of β CAP73 protein domains from deduced amino acid sequence. The ankyrin-like repeats were identified by sequence domain search, while the 100 amino acid α -helical domain was identified through secondary structure prediction. The epitope-containing region was determined by immunoblotting of the GST-fusion constructs indicated in A, where proteins generated from the β CAP73-F and β CAP73-N constructs were immunoreactive with the anti- β CAP73 mAb while β CAP73-C was not.

Figures 4-1, 4-2, 4-3, 4-4, 4-5, 4-6, 4-7, and 4-8: The cDNA sequence of bcap73 is shown, with the 5' and 3' untranslated regions. The entire nucleotide sequence is SEQ ID NO: 1. The nucleotide sequence which corresponds to the open reading frame (ORF) spans

nucleotide positions 392 to 4597 and is SEQ ID NO: 3. The deduced amino acid sequence which is coded in the ORF is shown as well and is SEQ ID NO: 2.

Figure 5: A northern blot analysis on bcap73 mRNA expression in various tissues. Transcript is detected predominantly in skeletal muscle, brain and heart.

Figure 6: Immunofluorescence photography showing the formation of novel membrane protrusions in bovine retinal pericytes which overexpress histidine-tagged recombinant bcap73. These rounded protrusions are predominantly located on the ventral regions of the cell. Recombinant bcap73 is found within these membrane protrusions. The left side shows filamentous actin visualized with rhodamine-conjugated phalloidin. The right side shows localization of recombinant bcap73 using INDIA probe (a horseradish peroxidase-conjugated nickel reagent) which identified the histidine tag, followed by rabbit anti-HRP and fluorescein-conjugated anti-rabbit antibodies.

Figure 7: Immunofluorescence photography showing the formation of aberrant cellular projections in bovine retinal pericytes which overexpress recombinant bcap73 domains fused to GFP (green fluorescent protein). CAP-C-GFP (bcap73 bases 3503-4736) and CAP-N-GFP (bcap73 bases 2430-3503) were transiently transfected into bovine retinal pericytes, causing these cells to project arborized membrane structures. Note that untransfected cells do not exhibit these protrusions, but remain flat. CAP-N-GFP expression is shown on top (A), CAP-C-GFP expression is shown below (B). Left and right sides are matched fluorescent and phase images.

Figure 8: A northern blot analysis showing that bcap73 transcript is down-regulated in endothelial cells which are responding to injury. Endothelial cells that are mechanically injured migrate into wound spaces in order to repair and re-populate the area. These crawling cells show a large decrease in bcap73 mRNA as an early response to the injury at 30, 60, and 90 minutes after injury. Here, this is compared to contact-inhibited, stationary cells (marked "con").

Figures 9-1, 9-2, 9-3, and 9-4: A sequence alignment of bcap73 cDNA (SEQ ID NO:1) against the *C. familiaris* C3VS gene (GenBank Accession No. X99145).

Figures 10-1, 10-2, and 10-3: A sequence alignment of bcap73 cDNA (SEQ ID NO:1) against Tentative Human Consensus (THC) Contiguous Sequences from the TIGR (Accession Nos. THC244788, THC186491, THC186491, THC213238).

Detailed Description of the Invention

The present invention is based, at least in part, on the discovery of novel actin binding protein (ABP) family members, referred to herein as "beta-cap73" or "βcap73" or "bcap73" nucleic acid and protein molecules. ABP molecules modulate the proliferation, motility, differentiation, and survival of a variety of cells of mesodermal and/or neuroectodermal and/or ectodermal and/or endodermal origin, including fibroblasts, cells of

the immune system, cells of the nervous system, cardiac muscle cells, skeletal muscle cells, vascular endothelial cells, vascular smooth muscle endothelial cells, and cells involved with repair of tissue injury.

The bcap73 molecules of the present invention may also be motility regulatory proteins that function to modulate intracellular actin distribution, actin activity, changes in cytoskeletal structure, and response to tissue injury. Thus, the bcap73 molecules of the present invention may play a role in tissue repair mechanisms. As used herein, the term "tissue repair mechanisms" include mechanisms which regulate 1) intracellular actin distribution, 2) actin activity, 3) changes in cytoskeletal structure, 4) cell motility and migration 5) cellular response to tissue damage, and/or 6) repair of tissue damage. The ability of some cells, (e.g. vascular endothelial cells, vascular smooth muscle cells, fibroblasts, and keratinocytes) to move in response to stimuli (e.g. injury) depends upon their ability to coordinate directional assembly and disassembly of actin filaments of the cytoskeleton. The activity and cellular distribution of actin monomers and polymers are governed, at least in part, by "actin binding proteins" (ABPs) which interact with actin moieties. The bcap73 molecules of the present invention may be involved in such regulation of actin (Figures 6 and 7). Thus, the bcap73 molecules, by participating in regulation of actin activity and cytoskeletal rearrangement, may themselves modulate tissue repair mechanisms and act as targets and therapeutic agents for controlling tissue repair mechanisms (Figures 1 and 8).

Aberrant or excessive or insufficient expression of ABPs and their functional relatives which are involved in the regulation of actin function and intracellular actin distribution and cellular motility can lead to perturbed cellular functions, which in turn can lead to cellular disorders (or exacerbate existing cellular disorders). As used herein, a "cellular disorder" includes a disorder, disease, or condition characterized by aberrant or insufficient cellular ability to move or migrate properly in response to certain stimuli (e.g. tissue damage), or inability to properly regulate actin function and distribution within the cell. Thus, the bcap73 molecules may act as novel diagnostic targets and therapeutic agents for controlling cellular disorders related to motility, including cancer (e.g. tumor angiogenesis and metastasis). Additionally, bcap73 molecules may act as novel therapeutic agents for ameliorating certain cellular disorders and conditions through their ability to migrate and to regulate tissue injury response. As used herein, the terms "cellular disorders" and "conditions" include cardiovascular disorders and epidermal wounds. As used herein, the term "cardiovascular disorder" includes a disease, disorder, or state involving the cardiovascular system, e.g., the heart, the blood vessels, and/or the blood. A cardiovascular disorder can be caused by an imbalance in arterial pressure, a malfunction of the heart, or an occlusion of a blood vessel, e.g., by a thrombus. Examples of such disorders include congenital heart defects (e.g., atrioventricular canal defects), hypertension, atherosclerosis,

coronary artery spasm, coronary artery disease, valvular disease, ischemia reperfusion injury, restenosis, arterial inflammation, vascular wall remodeling, ventricular remodeling, rapid ventricular pacing, coronary microembolism, tachycardia, bradycardia, pressure overload, aortic bending, coronary artery ligation, vascular heart disease, long-QT syndrome, congestive heart failure, sinus node dysfunction, atrial flutter, myocardial infarction, coronary artery spasm, arrhythmias, and cardiomyopathies. As used herein, the term "epidermal wounds" includes wounds suffered by burn victims, wounds suffered through surgical procedures, and wounds that are normally ameliorated through the actions of keratinocytes.

Bcap73-associated or related disorders also include disorders of tissues in which bcap73 is expressed, *e.g.*, cardiac tissue, vascular system, skeletal muscle, and tissues of the nervous system. Bcap73-associated or related disorders can furthermore include disorders of tissues which can be affected or impacted by tissue in which bcap73 is normally expressed.

The bcap73 molecules of the present invention were identified from an injury response-activated bovine endothelial cDNA library. Vascular endothelial cells and keratinocytes contain the ability to respond to injury. Accordingly, the bcap73 molecules may also act as novel diagnostic targets and therapeutic agents for controlling or enhancing injury repair in a variety of disorders, diseases, or conditions. For example, the bcap73 molecules may provide novel diagnostic targets and therapeutic agents for controlling or enhancing the response elicited through various forms of vascular tissue injury, *e.g.*, atherosclerosis, mechanical damage from balloon angioplasty, and tumor-induced angiogenesis.

The term "family" when referring to the protein and nucleic acid molecules of the invention is intended to mean two or more proteins or nucleic acid molecules having a common structural domain or motif and having sufficient amino acid or nucleotide sequence homology as defined herein. Such family members can be naturally or non-naturally occurring and can be from either the same or different species. For example, a family can contain a first protein of human origin, as well as other, distinct proteins of human origin or alternatively, can contain homologues of non-human origin, *e.g.*, bovine and monkey proteins. Members of a family may also have common functional characteristics.

For example, sequence conservation among bcap73-related family members indicates that these proteins are likely to include at least one ankyrin repeat domain. As used herein, the term "ankyrin repeat domain" includes an amino acid sequence and/or protein structure that has one or more occurrences of the consensus amino acid sequence for an ankyrin repeat domain which comprises the following pattern:

G-x-T- [PA] -L-H-x-A-A-x-x-G-x-x-x- [VI] - [VA] -x-x-L-L-x-x-G-A-x-x-N-x-x- [TD] (SEQ ID NO: 4)

The signature patterns or consensus patterns described herein are described according to the following designation: all amino acids are indicated according to their universal single letter designation; "x" designates any amino acid; amino acids in brackets indicates any one of the amino acids within the brackets, *e.g.*, [VI] indicates either V (valine) or I (isoleucine) in that amino acid position. Bovine bcap73 has such a signature pattern at about amino acid residues 55 to 85, 88 to 118, 121 to 151, 184 to 214, 217 to 247, and 250 to 280 of SEQ ID NO: 2.

By further example, the family of bcap73-related proteins are likely to comprise at least one, and preferably two, three, four, five, six, seven, eight, nine or more ankyrin repeat domains. As used herein, the term "ankyrin repeat domain" includes a protein domain involved in protein:protein interactions, having an amino acid sequence of about 20-40 amino acid residues and having a bit score for the alignment of the sequence to the ankyrin repeat domain of at least 1 (using hidden Markov model analysis; HMM). Preferably, an ankyrin repeat domain includes at least about 25-40, more preferably about 25-35 amino acid residues, or most preferably about 30-35 amino acids and has a bit score for the alignment of the sequence to the ankyrin repeat domain (HMM) of at least 3, 5, 10, 20, 30, 40, 50, or greater. The ankyrin repeat domain (HMM) has been assigned the PFAM Accession PF00023 (www.pfam.wustl.edu). Ankyrin repeats are described in, for example, Otto E. *et al.* (1991) *J. Biol. Chem.* 114:241-253, Hatada E.N. *et al.* (1992) *PNAS USA* 89:2489-2493, and Blank V.P. *et al.* (1992) *Trends Genet.* 8:144-149, the contents of which are incorporated herein by reference.

In another preferred embodiment, an ankyrin repeat domain includes at least about 20-80, or more preferably about 20-30 amino acid residues, and has at least 50-60% homology, preferably about 60-70%, more preferably about 70-80%, or about 80-90% homology with an ankyrin repeat domain of bovine bcap73 (residues 55 through 280 of SEQ ID NO: 2).

As a further example, sequence conservation among bcap73-related family members indicates that these proteins are likely to include at least one actin-binding domain. As used herein, the term "actin-binding domain" includes an amino acid sequence and/or protein structure that preferably associated with one or more specific surfaces of actin monomers and polymers.

In a preferred embodiment, an actin-binding domain among bcap73-related family members comprises a primary amino acid sequence which forms secondary and/or tertiary structures which comprise an alpha helical coiled coil domain. In a preferred embodiment, this domain would span at least one, more preferably two or three or more actin monomers. In a further preferred embodiment, this domain allows bcap73 to bind axially along the length of the actin filament at the actin filament end.

In another preferred embodiment, an actin-binding domain includes at least about 20-800, or more preferably about 20-450, or most preferably 50-150 or 100-120 amino acid residues, and has at least 50-60% homology, preferably about 60-70%, more preferably about 70-80%, or about 80-90% homology with an actin-binding domain of bovine bcap73. (located within about residues 940 through 1401, or within about residues 1120-1220 of SEQ ID NO: 2).

Accordingly, bcap73 proteins having at least 50-60% homology, preferably about 60-70%, more preferably about 70-80%, or about 80-90% homology with an ankyrin repeat domain of bovine bcap73 are within the scope of the invention. Furthermore, bcap73 proteins having at least 50-60% homology, preferably about 60-70%, more preferably about 70-80%, or about 80-90% homology with an actin binding domain of bovine bcap73 are also within the scope of the invention.

Isolated proteins of the present invention, preferably bcap73 proteins, have an amino acid sequence sufficiently identical to the amino acid sequence of SEQ ID NO: 2, or are encoded by a nucleotide sequence sufficiently identical to SEQ ID NO: 1 or 3. As used herein, the term "sufficiently identical" refers to a first amino acid or nucleotide sequence which contains a sufficient or minimum number of identical or equivalent (*e.g.*, an amino acid residue which has a similar side chain) amino acid residues or nucleotides to a second amino acid or nucleotide sequence such that the first and second amino acid or nucleotide sequences share common structural domains or motifs and/or a common functional activity. For example, amino acid or nucleotide sequences which share common structural domains have at least 30%, 40%, or 50% homology, preferably 60% homology, more preferably 70%-80%, and even more preferably 90-95% homology across the amino acid sequences of the domains and contain at least one and preferably two structural domains or motifs, are defined herein as sufficiently identical. Furthermore, amino acid or nucleotide sequences which share at least 30%, 40%, or 50%, preferably 60%, more preferably 70-80%, or 90-95% homology and share a common functional activity are defined herein as sufficiently identical.

As used interchangeably herein, a "bcap73 activity", "biological activity of bcap73" or "functional activity of bcap73", refers to an activity exerted by a bcap73 protein, polypeptide or nucleic acid molecule on a bcap73 responsive cell or tissue, or on a bcap73 protein substrate, as determined *in vivo*, or *in vitro*, according to standard techniques. In one embodiment, a bcap73 activity is a direct activity, such as an association with a bcap73-target molecule. As used herein, a "target molecule" or "binding partner" is a molecule with which a bcap73 protein binds or interacts in nature, such that bcap73-mediated function is achieved. A bcap73 target molecule can be a non-bcap73 molecule or a bcap73 protein or polypeptide of the present invention. In an exemplary embodiment, a bcap73 target molecule is a bcap73 substrate, *e.g.*, a β -actin or an ezrin molecule. Alternatively, a bcap73 activity is an indirect activity, such as a subcellular actin distribution or regulation of actin

function or cell motility or response to tissue injury, mediated by interaction of the bcap73 protein with a bcap73 substrate, *e.g.*, a β -actin or an ezrin molecule. Preferably, a bcap73 activity is the ability to act as an actin-binding factor and to modulate functions such as subcellular actin distribution, changes in cytoskeletal structure, cell motility, and response to injury.

Accordingly, another embodiment of the invention features isolated bcap73 proteins and polypeptides having a bcap73 activity. Preferred proteins are bcap73 proteins having at least one ankyrin repeat domain, and, preferably, a bcap73 activity. Other preferred proteins are bcap73 proteins having an actin binding domain and, preferably, a bcap73 activity. Yet other preferred proteins are bcap73 proteins having at least one ankyrin repeat domain and an actin binding domain and, preferably, a bcap73 activity. Additional preferred proteins have at least one ankyrin repeat domain and/or actin binding domain, and are, preferably, encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1 or 3.

The nucleotide sequence of the isolated bovine bcap73 cDNA and the predicted amino acid sequence of the bovine bcap73 polypeptide are SEQ ID NO: 1 and 2 respectively and are shown in Figure 4.

The bovine bcap73 gene, which is approximately 4736 nucleotides in length, encodes a protein of approximately 1401 amino acid residues in length, which has a predicted molecular weight of approximately 154 kDa, and an observed molecular weight of approximately 73 kDa.

Various aspects of the invention are described in further detail in the following subsections:

I. Isolated Nucleic Acid Molecules

One aspect of the invention pertains to isolated nucleic acid molecules that encode bcap73 proteins or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as hybridization probes to identify bcap73-encoding nucleic acid molecules (*e.g.*, bcap73 mRNA) and fragments for use as PCR primers for the amplification or mutation of bcap73 nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (*e.g.*, cDNA or genomic DNA) and RNA molecules (*e.g.*, mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.

The term "isolated nucleic acid molecule" includes nucleic acid molecules which are separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. For example, with regard to genomic DNA, the term "isolated" includes

nucleic acid molecules which are separated from the chromosome with which the genomic DNA is naturally associated. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (*i.e.*, sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived.

5 For example, in various embodiments, the isolated bcap73 nucleic acid molecule can contain less than about 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when
10 produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the present invention, *e.g.*, a nucleic acid molecule having the nucleotide sequence of SEQ ID NO: 1 or 3, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein.

15 Using all or portion of the nucleic acid sequence of SEQ ID NO: 1 or 3, as a hybridization probe, bcap73 nucleic acid molecules can be isolated using standard hybridization and cloning techniques (*e.g.*, as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

20 Moreover, a nucleic acid molecule encompassing all or a portion of SEQ ID NO: 1 or 3 can be isolated by the polymerase chain reaction (PCR) using synthetic oligonucleotide primers designed based upon the sequence of SEQ ID NO: 1 or 3.

A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers
25 according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to bcap73 nucleotide sequences can be prepared by standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

In a preferred embodiment, an isolated nucleic acid molecule of the invention
30 comprises the nucleotide sequence shown in SEQ ID NO: 1. The sequence of SEQ ID NO: 1 corresponds to the bovine bcap73 cDNA. This cDNA comprises sequences encoding the bovine bcap73 protein (*i.e.*, "the coding region", from nucleotides 392-4597), the 5' untranslated sequences (nucleotides 1-391), as well as 3' untranslated sequences (nucleotides 4598-4736). Alternatively, the nucleic acid molecule can comprise only the
35 coding region of SEQ ID NO: 1 (*e.g.*, nucleotides 392-4597, corresponding to SEQ ID NO: 3).

In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence shown

in SEQ ID NO: 1 or 3, or a portion of any of these nucleotide sequences. A nucleic acid molecule which is complementary to the nucleotide sequence shown in SEQ ID NO: 1 or 3, is one which is sufficiently complementary to the nucleotide sequence shown in SEQ ID NO: 1 or 3, such that it can hybridize to the nucleotide sequence shown in SEQ ID NO: 1 or 3, thereby forming a stable duplex.

In still another preferred embodiment, an isolated nucleic acid molecule of the present invention comprises a nucleotide sequence which is at least about 32.2%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 83%, 85%, 90%, 95%, 98% or more identical to the entire length of the nucleotide sequence shown in SEQ ID NO: 1 or 3, or a portion of any of these nucleotide sequences.

Moreover, the nucleic acid molecule of the invention can comprise only a portion of the nucleic acid sequence of SEQ ID NO: 1 or 3, for example, a fragment which can be used as a probe or primer or a fragment encoding a portion of a bcap73 protein, *e.g.*, a biologically active portion of a bcap73 protein. The nucleotide sequence determined from the cloning of the bcap73 gene allows for the generation of probes and primers designed for use in identifying and/or cloning other bcap73 family members, as well as bcap73 homologues from other species. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12 or 15, preferably about 20 or 25, more preferably about 30, 35, 40, 45, 50, 55, 60, 65, or 75 consecutive nucleotides of a sense sequence of SEQ ID NO: 1 or 3, of an anti-sense sequence of SEQ ID NO: 1 or 3, or of a naturally occurring allelic variant or mutant of SEQ ID NO: 1 or 3. In one embodiment, a nucleic acid molecule of the present invention comprises a nucleotide sequence which is greater than 1911, 1911-2000, 2000-2250, 2250-2500, 2500-2750, 2750-3000, 3000-3250, 3250-3500, 3500-3750, 3750-4000, 4000-4250, 4250-4500, 4500-4736, or more nucleotides in length and hybridizes under stringent hybridization conditions to a nucleic acid molecule of SEQ ID NO: 1 or 3. The lengths of nucleic acid molecules of the invention can be within a range using any one of the aforementioned numbers as the upper or lower limit of the range. For example, the nucleic acid molecules can be of a length greater than at least 1911 and/or 3000 nucleotides in length.

Probes based on the bcap73 nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In preferred embodiments, the probe further comprises a label group attached thereto, *e.g.*, the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissue which misexpress a bcap73 protein, such as by measuring a level of a bcap73-encoding nucleic acid in a sample of cells from a subject *e.g.*, detecting bcap73 mRNA levels or determining whether a genomic bcap73 gene has been mutated or deleted.

A nucleic acid fragment encoding a "biologically active portion of a bcap73 protein" can be prepared by isolating a portion of the nucleotide sequence of SEQ ID NO: 1 or 3, which encodes a polypeptide having a bcap73 biological activity (the biological activities of the bcap73 proteins are described herein), expressing the encoded portion of the bcap73 protein (*e.g.*, by recombinant expression *in vitro*) and assessing the activity of the encoded portion of the bcap73 protein.

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequence shown in SEQ ID NO: 1 or 3, due to degeneracy of the genetic code and thus encode the same bcap73 proteins as those encoded by the nucleotide sequence shown in SEQ ID NO: 1 or 3. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID NO: 2.

In addition to the bcap73 nucleotide sequences shown in SEQ ID NO: 1 or 3, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the bcap73 proteins may exist within a population (*e.g.*, the human population). Such genetic polymorphism in the bcap73 genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules which include an open reading frame encoding a bcap73 protein, preferably a mammalian bcap73 protein, and can further include non-coding regulatory sequences, and introns.

Allelic variants of bovine bcap73 include both functional and non-functional bcap73 proteins. Functional allelic variants are naturally occurring amino acid sequence variants of the bovine bcap73 proteins that maintain the ability to bind a bcap73 ligand or substrate and/or modulate subcellular distribution of actin and/or actin function and/or changes in cytoskeletal structure and/or cell motility and/or response to tissue injury. Functional allelic variants will typically contain only conservative substitution of one or more amino acids of SEQ ID NO: 2, or substitution, deletion or insertion of non-critical residues in non-critical regions of the protein.

Non-functional allelic variants are naturally occurring amino acid sequence variants of the bovine bcap73 proteins that do not have the ability to either bind a bcap73 ligand or substrate and/or modulate cell proliferation and/or migration mechanisms. Non-functional allelic variants will typically contain a non-conservative substitution, a deletion, or insertion or premature truncation of the amino acid sequence of SEQ ID NO: 2, or a substitution, insertion or deletion in critical residues or critical regions.

The present invention further provides non-bovine orthologues of the bovine bcap73 proteins. Orthologues of the bovine bcap73 proteins are proteins that are isolated from non-bovine organisms and possess the same bcap73 ligand binding and/or modulation of subcellular actin distribution and/or actin function and/or changes in cytoskeletal structure

and/or cell motility and/or response to tissue injury of the bovine bcap73 proteins. Orthologues of the bovine bcap73 proteins can readily be identified as comprising an amino acid sequence that is substantially identical to SEQ ID NO: 2.

Moreover, nucleic acid molecules encoding other bcap73 family members and, thus, which have a nucleotide sequence which differs from the bcap73 sequences of SEQ ID NO: 1 or 3 are intended to be within the scope of the invention. For example, another bcap73 cDNA can be identified based on the nucleotide sequence of bovine bcap73. Moreover, nucleic acid molecules encoding bcap73 proteins from different species, and which, thus, have a nucleotide sequence which differs from the bcap73 sequences of SEQ ID NO: 1 or 3 are intended to be within the scope of the invention. For example, a human bcap73 cDNA or a mouse bcap73 cDNA can be identified based on the nucleotide sequence of a bovine bcap73.

Nucleic acid molecules corresponding to natural allelic variants and homologues of the bcap73 cDNAs of the invention can be isolated based on their homology to the bcap73 nucleic acids disclosed herein using the cDNAs disclosed herein, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. Nucleic acid molecules corresponding to natural allelic variants and homologues of the bcap73 cDNAs of the invention can further be isolated by mapping to the same chromosome or locus as the bcap73 gene.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 15, 20, 25, 30 or more nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1 or 3. In other embodiment, the nucleic acid is at least 30, 50, 100, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 900, 1000, 1100, 1200, 1400, 1600, 1800, 2000, 2200, 2400, 2600, 2800, 3000, 3200, 3400, 3600, 3800, 4000, 4200, 4400, 4600 or more nucleotides in length. The nucleic acid molecules of the invention can be of a length within a range which uses any one of the aforementioned numbers as the upper or lower limit of the range. For example, the nucleic acid molecules can be of a length between at least 30 and 250 nucleotides in length.

As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% identical to each other typically remain hybridized to each other. Preferably, the conditions are such that sequences at least about 70%, more preferably at least about 80%, even more preferably at least about 85% or 90% identical to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or

more washes in 0.2 X SSC, 0.1% SDS at 50°C, preferably at 55°C, more preferably at 60°C, and even more preferably at 65°C. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NO: 1 or 3 corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (*e.g.*, encodes a natural protein).

In addition to naturally-occurring allelic variants of the bcap73 sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NO: 1 or 3, thereby leading to changes in the amino acid sequence of the encoded bcap73 proteins, without altering the functional ability of the bcap73 proteins. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence of SEQ ID NO: 1 or 3. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of bcap73 (*e.g.*, the sequence of SEQ ID NO: 2) without altering the biological activity, whereas an "essential" amino acid residue is required for biological activity. For example, amino acid residues that are conserved among the bcap73 proteins of the present invention, *e.g.*, those present in the actin-binding domain and/or the actin-binding domain, are predicted to be particularly unamenable to alteration. Furthermore, additional amino acid residues that are conserved between the bcap73 proteins of the present invention and other members of the ABP family are not likely to be amenable to alteration.

Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding bcap73 proteins that contain changes in amino acid residues that are not essential for activity. Such bcap73 proteins differ in amino acid sequence from SEQ ID NO: 2, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more identical to SEQ ID NO: 2.

An isolated nucleic acid molecule encoding a bcap73 protein identical to the protein of SEQ ID NO: 2, can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO: 1 or 3, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced into SEQ ID NO: 1 or 3, by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid,

glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in a bcap73 protein is preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a bcap73 coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for bcap73 biological activity to identify mutants that retain activity. Following mutagenesis of SEQ ID NO: 1 or 3, the encoded protein can be expressed recombinantly and the activity of the protein can be determined.

In a preferred embodiment, a mutant bcap73 protein can be assayed for the ability to (1) interact with a non-bcap73 protein molecule, *e.g.*, a bcap73 ligand or substrate; (2) activate a bcap73-dependent signal transduction pathway; or (3) modulate subcellular distribution of actin and/or actin function and/or changes in cytoskeletal structure and/or cell motility and/or response to tissue injury.

In addition to the nucleic acid molecules encoding bcap73 proteins described above, another aspect of the invention pertains to isolated nucleic acid molecules which are antisense thereto. An "antisense" nucleic acid comprises a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a protein, *e.g.*, complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid. The antisense nucleic acid can be complementary to an entire bcap73 coding strand, or to only a portion thereof. In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding bcap73. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues (*e.g.*, the coding region of bovine bcap73 corresponds to SEQ ID NO: 3). In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding bcap73. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (*i.e.*, also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding bcap73 disclosed herein (*e.g.*, SEQ ID NO: 3), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of bcap73 mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of bcap73 mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of bcap73 mRNA. An antisense oligonucleotide can be, for example,

about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or
5 variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, *e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine,
10 xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-
15 mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense
20 nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a
25 subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a bcap73 protein to thereby inhibit expression of the protein, *e.g.*, by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions
30 in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention include direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense
35 molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, *e.g.*, by linking the antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs

in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an α -anomeric nucleic acid molecule. An α -anomeric nucleic acid molecule forms specific
5 double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gaultier *et al.* (1987) *Nucleic Acids. Res.* 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue *et al.* (1987) *Nucleic Acids Res.* 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue *et al.* (1987) *FEBS Lett.* 215:327-330).

10 In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (*e.g.*, hammerhead ribozymes (described in Haselhoff and Gerlach (1988) *Nature* 334:585-591)) can be used to catalytically cleave
15 bcap73 mRNA transcripts to thereby inhibit translation of bcap73 mRNA. A ribozyme having specificity for a bcap73-encoding nucleic acid can be designed based upon the nucleotide sequence of a bcap73 cDNA disclosed herein (*i.e.*, SEQ ID NO: 1 or 3). For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be
20 cleaved in a bcap73-encoding mRNA. See, *e.g.*, Cech *et al.* U.S. Patent No. 4,987,071; and Cech *et al.* U.S. Patent No. 5,116,742. Alternatively, bcap73 mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, *e.g.*, Bartel, D. and Szostak, J.W. (1993) *Science* 261:1411-1418.

Alternatively, bcap73 gene expression can be inhibited by targeting nucleotide
25 sequences complementary to the regulatory region of the bcap73 (*e.g.*, the bcap73 promoter and/or enhancers) to form triple helical structures that prevent transcription of the bcap73 gene in target cells. See generally, Helene, C. (1991) *Anticancer Drug Des.* 6(6):569-84; Helene, C. *et al.* (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher, L.J. (1992) *Bioassays* 14(12):807-15.

30 In yet another embodiment, the bcap73 nucleic acid molecules of the present invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, *e.g.*, the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acid molecules can be modified to generate peptide nucleic acids (see Hyrup B. *et al.* (1996) *Bioorganic & Medicinal Chemistry* 4 (1):
35 5-23). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, *e.g.*, DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA

under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup B. *et al.* (1996) *supra*; Perry-O'Keefe *et al.* *Proc. Natl. Acad. Sci.* 93: 14670-675.

PNAs of bcap73 nucleic acid molecules can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, for example, inducing transcription or translation arrest or inhibiting replication. PNAs of bcap73 nucleic acid molecules can also be used in the analysis of single base pair mutations in a gene, (*e.g.*, by PNA-directed PCR clamping); as 'artificial restriction enzymes' when used in combination with other enzymes, (*e.g.*, S1 nucleases (Hyrup B. (1996) *supra*)); or as probes or primers for DNA sequencing or hybridization (Hyrup B. *et al.* (1996) *supra*; Perry-O'Keefe *supra*).

In another embodiment, PNAs of bcap73 can be modified, (*e.g.*, to enhance their stability or cellular uptake), by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of bcap73 nucleic acid molecules can be generated which may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, (*e.g.*, RNase H and DNA polymerases), to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup B. (1996) *supra*). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup B. (1996) *supra* and Finn P.J. *et al.* (1996) *Nucleic Acids Res.* 24 (17): 3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry and modified nucleoside analogs, *e.g.*, 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used as a between the PNA and the 5' end of DNA (Mag, M. *et al.* (1989) *Nucleic Acid Res.* 17: 5973-88). PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn P.J. *et al.* (1996) *supra*). Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment (Peterser, K.H. *et al.* (1975) *Bioorganic Med. Chem. Lett.* 5: 1119-11124).

In other embodiments, the oligonucleotide may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:6553-6556; Lemaitre *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:648-652; PCT Publication No. W088/09810) or the blood-brain barrier (see, *e.g.*, PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (See, *e.g.*, Krol *et al.* (1988) *Bio-Techniques* 6:958-976) or intercalating agents. (See, *e.g.*, Zon (1988) *Pharm. Res.* 5:539-549). To this end, the oligonucleotide

may be conjugated to another molecule, (e.g., a peptide, hybridization triggered cross-linking agent, transport agent, or hybridization-triggered cleavage agent).

II. Isolated bcap73 Proteins and Anti-bcap73 Antibodies

5 One aspect of the invention pertains to isolated bcap73 proteins, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise anti-bcap73 antibodies. In one embodiment, native bcap73 proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, bcap73 proteins are produced by
10 recombinant DNA techniques. Alternative to recombinant expression, a bcap73 protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the bcap73 protein is derived, or substantially free from chemical
15 precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of bcap73 protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. In one embodiment, the language "substantially free of cellular material" includes preparations of bcap73 protein having less than about 30% (by dry weight) of non-
20 bcap73 protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-bcap73 protein, still more preferably less than about 10% of non-bcap73 protein, and most preferably less than about 5% non-bcap73 protein. When the bcap73 protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, *i.e.*, culture medium represents less than
25 about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of bcap73 protein in which the protein is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. In one embodiment, the
30 language "substantially free of chemical precursors or other chemicals" includes preparations of bcap73 protein having less than about 30% (by dry weight) of chemical precursors or non-bcap73 chemicals, more preferably less than about 20% chemical precursors or non-bcap73 chemicals, still more preferably less than about 10% chemical precursors or non-bcap73 chemicals, and most preferably less than about 5% chemical
35 precursors or non-bcap73 chemicals.

As used herein, a "biologically active portion" of a bcap73 protein includes a fragment of a bcap73 protein which participates in an interaction between a bcap73 molecule and a non-bcap73 molecule. Biologically active portions of a bcap73 protein

include peptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of the bcap73 protein, *e.g.*, the amino acid sequence shown in SEQ ID NO: 2, which include less amino acids than the full length bcap73 proteins, and exhibit at least one activity of a bcap73 protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the bcap73 protein, *e.g.*, modulating cell proliferation mechanisms. A biologically active portion of a bcap73 protein can be a polypeptide which is, for example, 10, 25, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400 or more amino acids in length. Biologically active portions of a bcap73 protein can be used as targets for developing agents which modulate a bcap73 mediated activity, *e.g.*, modulation of subcellular distribution of actin and/or actin function and/or changes in cytoskeletal structure and/or cell motility and/or response to tissue injury.

In one embodiment, a biologically active portion of a bcap73 protein comprises at least one ankyrin repeat domain, and/or at least one actin-binding domain. It is to be understood that a preferred biologically active portion of a bcap73 protein of the present invention may contain at least one ankyrin repeat domain. Another preferred biologically active portion of a bcap73 protein may contain at least one actin-binding domain. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native bcap73 protein.

In a preferred embodiment, the bcap73 protein has an amino acid sequence shown in SEQ ID NO: 2. In other embodiments, the bcap73 protein is substantially identical to SEQ ID NO: 2, and retains the functional activity of the protein of SEQ ID NO: 2, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail in subsection I above. Accordingly, in another embodiment, the bcap73 protein is a protein which comprises an amino acid sequence at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more identical to SEQ ID NO: 2.

To determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-identical sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and even more preferably at least 70%, 80%, or 90% of the length of the reference sequence (*e.g.*, when aligning a second sequence to the bcap73 amino acid sequence of SEQ ID NO: 2 having 1401 amino acid residues, at least 420, preferably at least 560, more preferably at least 701, even more preferably at least 841, and even more preferably at least 981, 1121 or 1261 amino acid residues are aligned). The

amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (*J. Mol. Biol.* (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at <http://www.gcg.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Meyers and W. Miller (CABIOS, 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, *et al.* (1990) *J. Mol. Biol.* 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to bcap73 nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 100, wordlength = 3 to obtain amino acid sequences homologous to bcap73 protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.*, (1997) *Nucleic Acids Res.* 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (*e.g.*, XBLAST and NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>.

The invention also provides bcap73 chimeric or fusion proteins. As used herein, a bcap73 "chimeric protein" or "fusion protein" comprises a bcap73 polypeptide operatively

linked to a non-bcap73 polypeptide. A "bcap73 polypeptide" refers to a polypeptide having an amino acid sequence corresponding to bcap73, whereas a "non-bcap73 polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the bcap73 protein, *e.g.*, a protein which is different from the bcap73 protein and which is derived from the same or a different organism. Within a bcap73 fusion protein the bcap73 polypeptide can correspond to all or a portion of a bcap73 protein. In a preferred embodiment, a bcap73 fusion protein comprises at least one biologically active portion of a bcap73 protein. In another preferred embodiment, a bcap73 fusion protein comprises at least two biologically active portions of a bcap73 protein. Within the fusion protein, the term "operatively linked" is intended to indicate that the bcap73 polypeptide and the non-bcap73 polypeptide are fused in-frame to each other. The non-bcap73 polypeptide can be fused to the N-terminus or C-terminus of the bcap73 polypeptide.

For example, in one embodiment, the fusion protein is a GST-bcap73 fusion protein in which the bcap73 sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant bcap73.

In a further embodiment, the fusion protein is a 6xHis-bcap73 fusion protein in which six consecutive histidine residues are fused to the N-terminus, or the C-terminus, or embedded within the amino acid sequence of bcap73 protein. Such fusion proteins can facilitate the detection and chromatographic purification of recombinant bcap73 and associated proteins.

In another embodiment, the fusion protein is a bcap73 protein containing a heterologous signal sequence at its N-terminus. In certain host cells (*e.g.*, mammalian host cells), expression and/or secretion of bcap73 can be increased through use of a heterologous signal sequence.

The bcap73 fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject *in vivo*. The bcap73 fusion proteins can be used to affect the bioavailability of a bcap73 substrate. Use of bcap73 fusion proteins may be useful therapeutically for the treatment of disorders caused by, for example, (i) aberrant modification or mutation of a gene encoding a bcap73 protein; (ii) mis-regulation of the bcap73 gene; (iii) aberrant post-translational modification of a bcap73 protein; (iv) wildtype activity that is insufficient for therapeutic purposes; and (v) wildtype activity that is overabundant for therapeutic purposes.

Moreover, the bcap73-fusion proteins of the invention can be used as immunogens to produce anti-bcap73 antibodies in a subject, to purify bcap73 ligands and in screening assays to identify molecules which inhibit the interaction of bcap73 with a bcap73 substrate.

Preferably, a bcap73 chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the

different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel *et al.* John Wiley & Sons: 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (*e.g.*, a GST polypeptide). A bcap73-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the bcap73 protein.

The present invention also pertains to variants of the bcap73 proteins which function as either bcap73 agonists (mimetics) or as bcap73 antagonists. Variants of the bcap73 proteins can be generated by mutagenesis, *e.g.*, discrete point mutation or truncation of a bcap73 protein. An agonist of the bcap73 proteins can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of a bcap73 protein. An antagonist of a bcap73 protein can inhibit one or more of the activities of the naturally occurring form of the bcap73 protein by, for example, competitively modulating a bcap73-mediated activity of a bcap73 protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the bcap73 protein.

In one embodiment, variants of a bcap73 protein which function as either bcap73 agonists (mimetics) or as bcap73 antagonists can be identified by screening combinatorial libraries of mutants, *e.g.*, truncation mutants, of a bcap73 protein for bcap73 protein agonist or antagonist activity. In one embodiment, a variegated library of bcap73 variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of bcap73 variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential bcap73 sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (*e.g.*, for phage display) containing the set of bcap73 sequences therein. There are a variety of methods which can be used to produce libraries of potential bcap73 variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate

expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential bcap73 sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, *e.g.*, Narang, S.A. (1983) *Tetrahedron* 39:3; Itakura *et al.* (1984) *Annu. Rev. Biochem.* 53:323; Itakura *et al.* (1984) *Science* 198:1056; Ike *et al.* (1983) *Nucleic Acid Res.* 11:477.

In addition, libraries of fragments of a bcap73 protein coding sequence can be used to generate a variegated population of bcap73 fragments for screening and subsequent selection of variants of a bcap73 protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a bcap73 coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal, C-terminal and internal fragments of various sizes of the bcap73 protein.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of bcap73 proteins. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify bcap73 variants (Arkin and Yourvan (1992) *Proc. Natl. Acad. Sci. USA* 89:7811-7815; Delgrave *et al.* (1993) *Protein Engineering* 6(3):327-331).

In one embodiment, cell based assays can be exploited to analyze a variegated bcap73 library. For example, a library of expression vectors can be transfected into a cell line, *e.g.*, an endothelial cell line, which ordinarily responds to bcap73 in a particular bcap73 substrate-dependent manner. The transfected cells are then contacted with bcap73 and the effect of expression of the mutant on signaling by the bcap73 substrate can be detected, *e.g.*, by monitoring intracellular calcium, IP3, or diacylglycerol concentration, phosphorylation profile of intracellular proteins, cell proliferation and/or migration, or the activity of an bcap73-regulated transcription factor. Plasmid DNA can then be recovered from the cells

which score for inhibition, or alternatively, potentiation of signaling by the bcap73 substrate, and the individual clones further characterized.

An isolated bcap73 protein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind bcap73 using standard techniques for polyclonal and monoclonal antibody preparation. A full-length bcap73 protein can be used or, alternatively, the invention provides antigenic peptide fragments of bcap73 for use as immunogens. The antigenic peptide of bcap73 comprises at least 8 amino acid residues of the amino acid sequence shown in SEQ ID NO: 2 and encompasses an epitope of bcap73 such that an antibody raised against the peptide forms a specific immune complex with bcap73. Preferably, the antigenic peptide comprises at least 10 amino acid residues, more preferably at least 15 amino acid residues, even more preferably at least 20 amino acid residues, and most preferably at least 30 amino acid residues.

Preferred epitopes encompassed by the antigenic peptide are regions of bcap73 that are located on the surface of the protein, *e.g.*, hydrophilic regions, as well as regions with high antigenicity.

A bcap73 immunogen typically is used to prepare antibodies by immunizing a suitable subject, (*e.g.*, rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for example, recombinantly expressed bcap73 protein or a chemically synthesized bcap73 polypeptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent. Immunization of a suitable subject with an immunogenic bcap73 preparation induces a polyclonal anti-bcap73 antibody response.

Accordingly, another aspect of the invention pertains to anti-bcap73 antibodies. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, *i.e.*, molecules that contain an antigen binding site which specifically binds (immunoreacts with) an antigen, such as bcap73. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies that bind bcap73. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of bcap73. A monoclonal antibody composition thus typically displays a single binding affinity for a particular bcap73 protein with which it immunoreacts.

Polyclonal anti-bcap73 antibodies can be prepared as described above by immunizing a suitable subject with a bcap73 immunogen. The anti-bcap73 antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized bcap73. If desired, the

antibody molecules directed against bcap73 can be isolated from the mammal (*e.g.*, from the blood) and further purified by well known techniques, such as protein A chromatography to obtain the IgG fraction. At an appropriate time after immunization, *e.g.*, when the anti-bcap73 antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) *Nature* 256:495-497) (see also, Brown *et al.* (1981) *J. Immunol.* 127:539-46; Brown *et al.* (1980) *J. Biol. Chem.* 255:4980-83; Yeh *et al.* (1976) *Proc. Natl. Acad. Sci. USA* 76:2927-31; and Yeh *et al.* (1982) *Int. J. Cancer* 29:269-75), the more recent human B cell hybridoma technique (Kozbor *et al.* (1983) *Immunol Today* 4:72), the EBV-hybridoma technique (Cole *et al.* (1985), *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96) or trioma techniques. The technology for producing monoclonal antibody hybridomas is well known (see generally R. H. Kenneth, in *Monoclonal Antibodies: A New Dimension In Biological Analyses*, Plenum Publishing Corp., New York, New York (1980); E. A. Lerner (1981) *Yale J. Biol. Med.*, 54:387-402; M. L. Gefter *et al.* (1977) *Somatic Cell Genet.* 3:231-36). Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with a bcap73 immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds bcap73.

Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating an anti-bcap73 monoclonal antibody (see, *e.g.*, G. Galfre *et al.* (1977) *Nature* 266:55052; Gefter *et al.* *Somatic Cell Genet.*, cited *supra*; Lerner, *Yale J. Biol. Med.*, cited *supra*; Kenneth, *Monoclonal Antibodies*, cited *supra*). Moreover, the ordinarily skilled worker will appreciate that there are many variations of such methods which also would be useful. Typically, the immortal cell line (*e.g.*, a myeloma cell line) is derived from the same mammalian species as the lymphocytes. For example, murine hybridomas can be made by fusing lymphocytes from a mouse immunized with an immunogenic preparation of the present invention with an immortalized mouse cell line. Preferred immortal cell lines are mouse myeloma cell lines that are sensitive to culture medium containing hypoxanthine, aminopterin and thymidine ("HAT medium"). Any of a number of myeloma cell lines can be used as a fusion partner according to standard techniques, *e.g.*, the P3-NS1/1-Ag4-1, P3-x63-Ag8.653 or Sp2/O-Ag14 myeloma lines. These myeloma lines are available from ATCC. Typically, HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol ("PEG"). Hybridoma cells resulting from the fusion are then selected using HAT medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days because they are not transformed). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the

hybridoma culture supernatants for antibodies that bind bcap73, e.g., using a standard ELISA assay.

Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal anti-bcap73 antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with bcap73 to thereby isolate immunoglobulin library members that bind bcap73. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia *Recombinant Phage Antibody System*, Catalog No. 27-9400-01; and the Stratagene *SurfZAP™ Phage Display Kit*, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, Ladner *et al.* U.S. Patent No. 5,223,409; Kang *et al.* PCT International Publication No. WO 92/18619; Dower *et al.* PCT International Publication No. WO 91/17271; Winter *et al.* PCT International Publication WO 92/20791; Markland *et al.* PCT International Publication No. WO 92/15679; Breitling *et al.* PCT International Publication WO 93/01288; McCafferty *et al.* PCT International Publication No. WO 92/01047; Garrard *et al.* PCT International Publication No. WO 92/09690; Ladner *et al.* PCT International Publication No. WO 90/02809; Fuchs *et al.* (1991) *Bio/Technology* 9:1370-1372; Hay *et al.* (1992) *Hum. Antibod. Hybridomas* 3:81-85; Huse *et al.* (1989) *Science* 246:1275-1281; Griffiths *et al.* (1993) *EMBO J* 12:725-734; Hawkins *et al.* (1992) *J. Mol. Biol.* 226:889-896; Clarkson *et al.* (1991) *Nature* 352:624-628; Gram *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:3576-3580; Garrad *et al.* (1991) *Bio/Technology* 9:1373-1377; Hoogenboom *et al.* (1991) *Nuc. Acid Res.* 19:4133-4137; Barbas *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88:7978-7982; and McCafferty *et al.* *Nature* (1990) 348:552-554.

Additionally, recombinant anti-bcap73 antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in Robinson *et al.* International Application No. PCT/US86/02269; Akira, *et al.* European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison *et al.* European Patent Application 173,494; Neuberger *et al.* PCT International Publication No. WO 86/01533; Cabilly *et al.* U.S. Patent No. 4,816,567; Cabilly *et al.* European Patent Application 125,023; Better *et al.* (1988) *Science* 240:1041-1043; Liu *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:3439-3443; Liu *et al.* (1987) *J. Immunol.* 139:3521-3526; Sun *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:214-218; Nishimura *et al.* (1987) *Canc. Res.* 47:999-1005; Wood *et al.* (1985) *Nature* 314:446-449; and Shaw *et al.* (1988) *J. Natl. Cancer Inst.* 80:1553-1559; Morrison, S. L. (1985) *Science* 229:1202-1207; Oi *et al.* (1986) *BioTechniques* 4:214; Winter U.S. Patent 5,225,539; Jones *et al.* (1986) *Nature* 321:552-

525; Verhoeyan *et al.* (1988) *Science* 239:1534; and Beidler *et al.* (1988) *J. Immunol.* 141:4053-4060.

An anti-bcap73 antibody (*e.g.*, monoclonal antibody) can be used to isolate bcap73 by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-bcap73 antibody can facilitate the purification of natural bcap73 from cells and of recombinantly produced bcap73 expressed in host cells. Moreover, an anti-bcap73 antibody can be used to detect bcap73 protein (*e.g.*, in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the bcap73 protein. Anti-bcap73 antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, *e.g.*, to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (*i.e.*, physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

III. Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a bcap73 protein (or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly

used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (*e.g.*, in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cells and those which direct expression of the nucleotide sequence only in certain host cells (*e.g.*, tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (*e.g.*, bcap73 proteins, mutant forms of bcap73 proteins, fusion proteins, and the like).

The recombinant expression vectors of the invention can be designed for expression of bcap73 proteins in prokaryotic or eukaryotic cells. For example, bcap73 proteins can be expressed in bacterial cells such as *E. coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion

expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D.B. and Johnson, K.S. (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Purified fusion proteins can be utilized in bcap73 activity assays, (e.g., direct assays or competitive assays described in detail below), or to generate antibodies specific for bcap73 proteins, for example. In a preferred embodiment, a bcap73 fusion protein expressed in a retroviral expression vector of the present invention can be utilized to infect bone marrow cells which are subsequently transplanted into irradiated recipients. The pathology of the subject recipient is then examined after sufficient time has passed (e.g., six (6) weeks).

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann *et al.*, (1988) *Gene* 69:301-315) and pET 11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 60-89). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter.

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada *et al.*, (1992) *Nucleic Acids Res.* 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the bcap73 expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1 (Baldari, *et al.*, (1987) *Embo J.* 6:229-234), pMFa (Kurjan and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz *et al.*, (1987) *Gene* 54:113-123), pYES2 (Invitrogen Corporation, San Diego, CA), and picZ (Invitrogen Corp, San Diego, CA).

Alternatively, bcap73 proteins can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (*e.g.*, Sf 9 cells) include the pAc series (Smith *et al.* (1983) *Mol. Cell Biol.* 3:2156-2165) and the pVL series (Lucklow and Summers (1989) *Virology* 170:31-39).

5 In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, B. (1987) *Nature* 329:840) and pMT2PC (Kaufman *et al.* (1987) *EMBO J.* 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For
10 example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook, J., Fritsch, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

15 In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (*e.g.*, tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert *et al.* (1987) *Genes Dev.* 1:268-277),
20 lymphoid-specific promoters (Calame and Eaton (1988) *Adv. Immunol.* 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) *EMBO J.* 8:729-733) and immunoglobulins (Banerji *et al.* (1983) *Cell* 33:729-740; Queen and Baltimore (1983) *Cell* 33:741-748), neuron-specific promoters (*e.g.*, the neurofilament promoter; Byrne and Ruddle (1989) *Proc. Natl. Acad. Sci. USA* 86:5473-5477), pancreas-specific promoters
25 (Edlund *et al.* (1985) *Science* 230:912-916), and mammary gland-specific promoters (*e.g.*, milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) *Science* 249:374-379) and the α -fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev.* 3:537-546). Also known in the art are
30 eukaryotic promoters which are specific for vascular endothelial cells (for example, the tie-2 promoter) and eukaryotic promoters which are specific for vascular smooth muscle cells (for example, the SM22 promoter) and eukaryotic promoters which are specific for keratinocytes. In a preferred embodiment, tissue-specific promoters are used to direct expression of bcap73 molecules of the invention in vascular smooth muscle cells and/or
35 vascular endothelial cells in order to ameliorate vascular and/or arterial injury, including injury related to arterial occlusion and/or atherosclerosis and/or balloon angioplasty. In a further preferred embodiment, tissue specific promoters are used to direct expression of bcap73 molecules of the invention to enhance the reparative response of keratinocytes

and/or fibroblasts to epidermal wounds, including burns and wounds from surgery. In a further preferred embodiment, tissue specific promoters are used to direct expression of bcap73 molecules of the invention to hamper or block endothelial migration associated with certain angiogenesis event; *e.g.* those associated with tumors and carcinomas.

5 The expression characteristics of an endogenous bcap73 gene within a cell line or microorganism may be modified by inserting a heterologous DNA regulatory element into the genome of a stable cell line or cloned microorganism such that the inserted regulatory element is operatively linked with the endogenous bcap73 gene. For example, an endogenous bcap73 gene which is normally "transcriptionally silent", *i.e.*, a bcap73 gene
10 which is normally not expressed, or is expressed only at very low levels in a cell line or microorganism, may be activated by inserting a regulatory element which is capable of promoting the expression of a normally expressed gene product in that cell line or microorganism. Alternatively, a transcriptionally silent, endogenous bcap73 gene may be activated by insertion of a promiscuous regulatory element that works across cell types.

15 A heterologous regulatory element may be inserted into a stable cell line or cloned microorganism, such that it is operatively linked with an endogenous bcap73 gene, using techniques, such as targeted homologous recombination, which are well known to those of skill in the art, and described, *e.g.*, in Chappel, U.S. Patent No. 5,272,071; PCT publication No. WO 91/06667, published May 16, 1991.

20 The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to bcap73 mRNA. Regulatory sequences operatively linked to a nucleic acid
25 cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic
30 acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub, H. *et al.*, Antisense RNA as a molecular tool for genetic analysis, *Reviews - Trends in Genetics*, Vol. 1(1) 1986.

35 Another aspect of the invention pertains to host cells into which a bcap73 nucleic acid molecule of the invention is introduced, *e.g.*, a bcap73 nucleic acid molecule within a recombinant expression vector or a bcap73 nucleic acid molecule containing sequences which allow it to homologously recombine into a specific site of the host cell's genome.

The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, a bcap73 protein can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (*e.g.*, DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (*Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989*), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (*e.g.*, resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding a bcap73 protein or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (*e.g.*, cells that have incorporated the selectable marker gene will survive, while the other cells die).

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (*i.e.*, express) a bcap73 protein. Accordingly, the invention further provides methods for producing a bcap73 protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of the invention (into which a recombinant expression vector encoding a bcap73 protein has been introduced) in a suitable medium such that a bcap73 protein is produced. In another embodiment, the method further comprises isolating a bcap73 protein from the medium or the host cell.

The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which bcap73-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous bcap73 sequences have been introduced into their genome or homologous recombinant animals in which endogenous bcap73 sequences have been altered. Such animals are useful for studying the function and/or activity of a bcap73 and for identifying and/or evaluating modulators of bcap73 activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, and the like. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous bcap73 gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, *e.g.*, an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing a bcap73-encoding nucleic acid into the male pronuclei of a fertilized oocyte, *e.g.*, by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The bcap73 cDNA sequence of SEQ ID NO: 1 can be introduced as a transgene into the genome of a non-human animal. Alternatively, a non-human homologue of a human bcap73 gene, such as a mouse or rat bcap73 gene, can be used as a transgene. Alternatively, a bcap73 gene homologue, such as another bcap73 family member, can be isolated based on hybridization to the bcap73 cDNA sequences of SEQ ID NO: 1 (described further in subsection I above) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to a bcap73 transgene to direct expression of a bcap73 protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, both by Leder *et al.*, U.S. Patent No. 4,873,191 by Wagner *et al.* and in Hogan, B., *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of a bcap73 transgene in its genome and/or expression of

bcap73 mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding a bcap73 protein can further be bred to other transgenic animals carrying other transgenes.

5 To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a bcap73 gene into which a deletion, addition or substitution has been introduced to thereby alter, *e.g.*, functionally disrupt, the bcap73 gene. The bcap73 gene can be a bovine gene (*e.g.*, the cDNA of SEQ ID NO: 3), but more preferably, is a non-human
10 homologue of a bovine bcap73 gene (*e.g.*, a cDNA isolated by stringent hybridization with the nucleotide sequence of SEQ ID NO: 1). For example, a mouse bcap73 gene can be used to construct a homologous recombination nucleic acid molecule, *e.g.*, a vector, suitable for altering an endogenous bcap73 gene in the mouse genome. In a preferred embodiment, the homologous recombination nucleic acid molecule is designed such that, upon homologous recombination, the endogenous bcap73 gene is functionally disrupted (*i.e.*, no longer
15 encodes a functional protein; also referred to as a "knock out" vector). Alternatively, the homologous recombination nucleic acid molecule can be designed such that, upon homologous recombination, the endogenous bcap73 gene is mutated or otherwise altered but still encodes functional protein (*e.g.*, the upstream regulatory region can be altered to thereby alter the expression of the endogenous bcap73 protein). In the homologous
20 recombination nucleic acid molecule, the altered portion of the bcap73 gene is flanked at its 5' and 3' ends by additional nucleic acid sequence of the bcap73 gene to allow for homologous recombination to occur between the exogenous bcap73 gene carried by the homologous recombination nucleic acid molecule and an endogenous bcap73 gene in a cell, *e.g.*, an embryonic stem cell. The additional flanking bcap73 nucleic acid sequence is of
25 sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the homologous recombination nucleic acid molecule (see, *e.g.*, Thomas, K.R. and Capecchi, M. R. (1987) *Cell* 51:503 for a description of homologous recombination vectors). The homologous recombination nucleic acid molecule is introduced into a cell, *e.g.*, an
30 embryonic stem cell line (*e.g.*, by electroporation) and cells in which the introduced bcap73 gene has homologously recombined with the endogenous bcap73 gene are selected (see *e.g.*, Li, E. *et al.* (1992) *Cell* 69:915). The selected cells can then injected into a blastocyst of an animal (*e.g.*, a mouse) to form aggregation chimeras (see *e.g.*, Bradley, A. in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E.J. Robertson, ed. (IRL, Oxford, 1987) pp. 113-152). A chimeric embryo can then be implanted into a suitable
35 pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline

transmission of the transgene. Methods for constructing homologous recombination nucleic acid molecules, *e.g.*, vectors, or homologous recombinant animals are described further in Bradley, A. (1991) *Current Opinion in Biotechnology* 2:823-829 and in PCT International Publication Nos.: WO 90/11354 by Le Mouellec *et al.*; WO 91/01140 by Smithies *et al.*;
5 WO 92/0968 by Zijlstra *et al.*; and WO 93/04169 by Berns *et al.*

In another embodiment, transgenic non-human animals can be produced which contain selected systems which allow for regulated expression of the transgene. One example of such a system is the *cre/loxP* recombinase system of bacteriophage P1. For a description of the *cre/loxP* recombinase system, see, *e.g.*, Lakso *et al.* (1992) *Proc. Natl.*
10 *Acad. Sci. USA* 89:6232-6236. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman *et al.* (1991) *Science* 251:1351-1355. If a *cre/loxP* recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the *Cre* recombinase and a selected protein are required. Such animals can be provided through the construction of "double"
15 transgenic animals, *e.g.*, by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. *et al.* (1997) *Nature* 385:810-813 and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, *e.g.*, a
20 somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, *e.g.*, through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The
25 offspring borne of this female foster animal will be a clone of the animal from which the cell, *e.g.*, the somatic cell, is isolated.

IV. Pharmaceutical Compositions

The bcap73 nucleic acid molecules, fragments of bcap73 proteins, and anti-bcap73
30 antibodies (also referred to herein as "active compounds") of the invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings,
35 antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the

compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include
5 parenteral, *e.g.*, intravenous, intradermal, subcutaneous, oral (*e.g.*, inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl
10 alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose
15 vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF,
20 Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol,
25 propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic
30 acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

35 Sterile injectable solutions can be prepared by incorporating the active compound (*e.g.*, a fragment of a bcap73 protein or an anti-bcap73 antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by

incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active
5 ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and
10 used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or
15 compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

20 For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, *e.g.*, a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be
25 permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

30 The compounds can also be prepared in the form of suppositories (*e.g.*, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release
35 formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be

obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Compounds which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC₅₀ (*i.e.*, the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

As defined herein, a therapeutically effective amount of protein or polypeptide (*i.e.*, an effective dosage) ranges from about 0.001 to 30 mg/kg body weight, preferably about 0.01 to 25 mg/kg body weight, more preferably about 0.1 to 20 mg/kg body weight, and even more preferably about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to

6 mg/kg body weight. The skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a protein, polypeptide, or antibody can include a single treatment or, preferably, can include a series of treatments.

In a preferred example, a subject is treated with antibody, protein, or polypeptide in the range of between about 0.1 to 20 mg/kg body weight, one time per week for between about 1 to 10 weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7 weeks, and even more preferably for about 4, 5, or 6 weeks. It will also be appreciated that the effective dosage of antibody, protein, or polypeptide used for treatment may increase or decrease over the course of a particular treatment. Changes in dosage may result and become apparent from the results of diagnostic assays as described herein.

The present invention encompasses agents which modulate expression or activity.

An agent may, for example, be a small molecule. For example, such small molecules include, but are not limited to, peptides, peptidomimetics, amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorganic compounds (*i.e.*, including heteroorganic and organometallic compounds) having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds. It is understood that appropriate doses of small molecule agents depends upon a number of factors within the ken of the ordinarily skilled physician, veterinarian, or researcher. The dose(s) of the small molecule will vary, for example, depending upon the identity, size, and condition of the subject or sample being treated, further depending upon the route by which the composition is to be administered, if applicable, and the effect which the practitioner desires the small molecule to have upon the nucleic acid or polypeptide of the invention.

Exemplary doses include milligram or microgram amounts of the small molecule per kilogram of subject or sample weight (*e.g.*, about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram. It is furthermore understood that appropriate doses of a small molecule depend upon the potency of the small molecule with respect to the expression or activity to be modulated. Such appropriate doses may be determined using the assays described herein. When one or more of these small molecules is to be administered to an animal (*e.g.*, a human) in order to modulate expression or activity of a polypeptide or nucleic acid of the invention, a

physician, veterinarian, or researcher may, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained. In addition, it is understood that the specific dose level for any particular animal subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated.

Further, an antibody (or fragment thereof) may be conjugated to a therapeutic moiety such as a cytotoxin, a therapeutic agent or a radioactive metal ion. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (*e.g.*, methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (*e.g.*, mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (*e.g.*, daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (*e.g.*, dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (*e.g.*, vincristine and vinblastine).

The conjugates of the invention can be used for modifying a given biological response, the drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, .alpha.-interferon, .beta.-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, *e.g.*, Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in *Controlled Drug Delivery* (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in

Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and
 5 Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", Immunol. Rev., 62:119-58 (1982). Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980.

The nucleic acid molecules of the invention can be inserted into vectors and used as
 10 gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Patent 5,328,470), stereotactic injection (see e.g., Chen et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:3054-3057), or by balloon catheter in conjunction with angioplasty. The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise
 15 a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system. Cells types which can be modified for gene therapy purposes include hematopoietic stem cells, myoblasts, hepatocytes, lymphocytes, skin
 20 epithelium and airway epithelium. For further descriptions of cell types, genes and methods for gene therapy see e.g., Wilson, J.M et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:3014-3018; Armentano, D. et al. (1990) *Proc. Natl. Acad. Sci. USA* 87:6141-6145; Wolff, J.A. et al. (1990) *Science* 247:1465-1468; Chowdhury, J.R. et al. (1991) *Science* 254:1802-1805; Ferry, N. et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:8377-8381; Wilson, J.M. et al. (1992)
 25 *J. Biol. Chem.* 267:963-967; Quantin, B. et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:2581-2584; Dai, Y. et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:10892-10895; van Beusechem, V.W. et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:7640-7644; Rosenfeld, M.A. et al. (1992) *Cell* 68:143-155; Kay, M.A. et al. (1992) *Human Gene Therapy* 3:641-647; Cristiano, R.J. et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:2122-2126; Hwu, P. et al. (1993) *J. Immunol.*
 30 150:4104-4115; and Herz, J. and Gerard, R.D. (1993) *Proc. Natl. Acad. Sci. USA* 90:2812-2816.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

35 V. Uses and Methods of the Invention

The nucleic acid molecules, proteins, protein homologues, and antibodies described herein can be used in one or more of the following methods: a) screening assays; b) predictive medicine (e.g., diagnostic assays, prognostic assays, monitoring clinical trials,

and pharmacogenetics); and c) methods of treatment (*e.g.*, therapeutic and prophylactic). As described herein, a bcap73 protein of the invention has one or more of the following activities: (1) it interacts with a non-bcap73 protein molecule, *e.g.*, a bcap73 substrate, such as an actin molecule or an ezrin molecule; (2) it is involved with intracellular distribution and activity of actin; (3) it is involved in regulating changes in cytoskeletal structure; (4) it is involved with mechanisms of cell motility; and (5) it is involved with mechanisms of response to tissue damage and repair of tissue damage, and, thus, can be used to, for example, (1) interact with a non-bcap73 protein molecule, *e.g.*, a bcap73 substrate, such as an actin molecule or an ezrin molecule; (2) affect intracellular distribution and activity of actin; (3) regulate changes in cytoskeletal structure; (4) affect mechanisms of cell motility; and (5) affect mechanisms of response to tissue damage and repair of tissue damage.

The isolated nucleic acid molecules of the invention can be used, for example, to express bcap73 protein (*e.g.*, via a recombinant expression vector in a host cell in gene therapy applications), to detect bcap73 mRNA (*e.g.*, in a biological sample) or a genetic alteration in a bcap73 gene, and to modulate bcap73 activity, as described further below. The bcap73 proteins can be used to treat disorders characterized by insufficient or excessive production of a bcap73 substrate or production of bcap73 inhibitors. In addition, the bcap73 proteins can be used to screen for naturally occurring bcap73 substrates, to screen for drugs or compounds which modulate bcap73 activity, as well as to treat disorders characterized by insufficient or excessive production of bcap73 protein or production of bcap73 protein forms which have decreased, aberrant or unwanted activity compared to bcap73 wild type protein (*e.g.*, cell motility disorders, cytoskeletal disorders neurodegenerative disorders, cardiovascular disorders, or tissue repair). Moreover, the anti-bcap73 antibodies of the invention can be used to detect and isolate bcap73 proteins, regulate the bioavailability of bcap73 proteins, and modulate bcap73 activity.

A. Screening Assays:

The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, *i.e.*, candidate or test compounds or agents (*e.g.*, peptides, peptidomimetics, small molecules or other drugs) which bind to bcap73 proteins, have a stimulatory or inhibitory effect on, for example, bcap73 expression or bcap73 activity, or have a stimulatory or inhibitory effect on, for example, the expression or activity of bcap73 substrate.

In one embodiment, the invention provides assays for screening candidate or test compounds which are substrates of a bcap73 protein or polypeptide or biologically active portion thereof. In another embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of a bcap73 protein or polypeptide or biologically active portion thereof. The test compounds of the present

invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K.S. (1997) *Anticancer Drug Des.* 12:145).

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt *et al.* (1993) *Proc. Natl. Acad. Sci. U.S.A.* 90:6909; Erb *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:11422; Zuckermann *et al.* (1994). *J. Med. Chem.* 37:2678; Cho *et al.* (1993) *Science* 261:1303; Carrell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2059; Carell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2061; and in Gallop *et al.* (1994) *J. Med. Chem.* 37:1233.

Libraries of compounds may be presented in solution (*e.g.*, Houghten (1992) *Biotechniques* 13:412-421), or on beads (Lam (1991) *Nature* 354:82-84), chips (Fodor (1993) *Nature* 364:555-556), bacteria (Ladner USP 5,223,409), spores (Ladner USP '409), plasmids (Cull *et al.* (1992) *Proc Natl Acad Sci USA* 89:1865-1869) or on phage (Scott and Smith (1990) *Science* 249:386-390); (Devlin (1990) *Science* 249:404-406); (Cwirla *et al.* (1990) *Proc. Natl. Acad. Sci.* 87:6378-6382); (Felici (1991) *J. Mol. Biol.* 222:301-310); (Ladner *supra.*).

In one embodiment, an assay is a cell-based assay in which a cell which expresses a bcap73 protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to modulate bcap73 activity is determined. Determining the ability of the test compound to modulate bcap73 activity can be accomplished by monitoring, for example, intracellular calcium, IP3, or diacylglycerol concentration, phosphorylation profile of intracellular proteins, cell proliferation and/or migration, or the activity of an bcap73-regulated transcription factor. The cell, for example, can be of mammalian origin, *e.g.*, an endothelial cell.

The ability of the test compound to modulate bcap73 binding to a substrate or to bind to bcap73 can also be determined. Determining the ability of the test compound to modulate bcap73 binding to a substrate can be accomplished, for example, by coupling the bcap73 substrate with a radioisotope or enzymatic label such that binding of the bcap73 substrate to bcap73 can be determined by detecting the labeled bcap73 substrate in a complex.

Alternatively, bcap73 could be coupled with a radioisotope or enzymatic label to monitor the ability of a test compound to modulate bcap73 binding to a bcap73 substrate in a complex. Determining the ability of the test compound to bind bcap73 can be accomplished, for example, by coupling the compound with a radioisotope or enzymatic label such that binding of the compound to bcap73 can be determined by detecting the

labeled bcap73 compound in a complex. For example, compounds (*e.g.*, bcap73 substrates) can be labeled with ^{125}I , ^{35}S , ^{14}C , or ^3H , either directly or indirectly, and the radioisotope detected by direct counting of radioemmission or by scintillation counting. Alternatively, compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.

It is also within the scope of this invention to determine the ability of a compound (*e.g.*, a bcap73 substrate) to interact with bcap73 without the labeling of any of the interactants. For example, a microphysiometer can be used to detect the interaction of a compound with bcap73 without the labeling of either the compound or the bcap73. McConnell, H. M. *et al.* (1992) *Science* 257:1906-1912. As used herein, a "microphysiometer" (*e.g.*, Cytosensor) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between a compound and bcap73.

In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a bcap73 target molecule (*e.g.*, a bcap73 substrate) with a test compound and determining the ability of the test compound to modulate (*e.g.*, stimulate or inhibit) the activity of the bcap73 target molecule. Determining the ability of the test compound to modulate the activity of a bcap73 target molecule can be accomplished, for example, by determining the ability of the bcap73 protein to bind to or interact with the bcap73 target molecule.

Determining the ability of the bcap73 protein or a biologically active fragment thereof, to bind to or interact with a bcap73 target molecule can be accomplished by one of the methods described above for determining direct binding. In a preferred embodiment, determining the ability of the bcap73 protein to bind to or interact with a bcap73 target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (*i.e.*, intracellular Ca^{2+} , diacylglycerol, IP_3 , and the like), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising a target-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, *e.g.*, luciferase), or detecting a target-regulated cellular response.

In yet another embodiment, an assay of the present invention is a cell-free assay in which a bcap73 protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to bind to the bcap73 protein or biologically active portion thereof is determined. Preferred biologically active portions of the bcap73 proteins to be used in assays of the present invention include fragments which participate in

interactions with non-bcap73 molecules, *e.g.*, fragments with high surface probability scores. Binding of the test compound to the bcap73 protein can be determined either directly or indirectly as described above. In a preferred embodiment, the assay includes contacting the bcap73 protein or biologically active portion thereof with a known compound
5 which binds bcap73 to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a bcap73 protein, wherein determining the ability of the test compound to interact with a bcap73 protein comprises determining the ability of the test compound to preferentially bind to bcap73 or biologically active portion thereof as compared to the known compound.

10 In another embodiment, the assay is a cell-free assay in which a bcap73 protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to modulate (*e.g.*, stimulate or inhibit) the activity of the bcap73 protein or biologically active portion thereof is determined. Determining the ability of the test compound to modulate the activity of a bcap73 protein can be accomplished, for example,
15 by determining the ability of the bcap73 protein to bind to a bcap73 target molecule by one of the methods described above for determining direct binding. Determining the ability of the bcap73 protein to bind to a bcap73 target molecule can also be accomplished using a technology such as real-time Biomolecular Interaction Analysis (BIA). Sjolander, S. and Urbaniczky, C. (1991) *Anal. Chem.* 63:2338-2345 and Szabo *et al.* (1995) *Curr. Opin. Struct. Biol.* 5:699-705. As used herein, "BIA" is a technology for studying biospecific interactions in real time, without labeling any of the interactants (*e.g.*, BIAcore). Changes in the optical phenomenon of surface plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules.

In an alternative embodiment, determining the ability of the test compound to
25 modulate the activity of a bcap73 protein can be accomplished by determining the ability of the bcap73 protein to further modulate the activity of a downstream effector of a bcap73 target molecule. For example, the activity of the effector molecule on an appropriate target can be determined or the binding of the effector to an appropriate target can be determined as previously described.

30 In yet another embodiment, the cell-free assay involves contacting a bcap73 protein or biologically active portion thereof with a known compound which binds the bcap73 protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with the bcap73 protein, wherein determining the ability of the test compound to interact with the bcap73 protein comprises
35 determining the ability of the bcap73 protein to preferentially bind to or modulate the activity of a bcap73 target molecule.

In more than one embodiment of the above assay methods of the present invention, it may be desirable to immobilize either bcap73 or its target molecule to facilitate separation

of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to a bcap73 protein, or interaction of a bcap73 protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix. For example, glutathione-S-transferase/ bcap73 fusion proteins or glutathione-S-transferase/target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or bcap73 protein, and the mixture incubated under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtitre plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of bcap73 binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either a bcap73 protein or a bcap73 target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated bcap73 protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with bcap73 protein or target molecules but which do not interfere with binding of the bcap73 protein to its target molecule can be derivatized to the wells of the plate, and unbound target or bcap73 protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the bcap73 protein or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the bcap73 protein or target molecule.

In another embodiment, modulators of bcap73 expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of bcap73 mRNA or protein in the cell is determined. The level of expression of bcap73 mRNA or protein in the presence of the candidate compound is compared to the level of expression of bcap73 mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of bcap73 expression based on this comparison. For example, when expression of bcap73 mRNA or protein is greater (statistically significantly

greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of bcap73 mRNA or protein expression.

Alternatively, when expression of bcap73 mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of bcap73 mRNA or protein expression. The level of bcap73 mRNA or protein expression in the cells can be determined by methods described herein for detecting bcap73 mRNA or protein.

In yet another aspect of the invention, the bcap73 proteins can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, *e.g.*, U.S. Patent No. 5,283,317; Zervos *et al.* (1993) *Cell* 72:223-232; Madura *et al.* (1993) *J. Biol. Chem.* 268:12046-12054; Bartel *et al.* (1993) *Biotechniques* 14:920-924; Iwabuchi *et al.* (1993) *Oncogene* 8:1693-1696; and Brent WO94/10300), to identify other proteins, which bind to or interact with bcap73 ("bcap73-binding proteins" or "bcap73-bp") and are involved in bcap73 activity. Such bcap73-binding proteins are also likely to be involved in the propagation of signals by the bcap73 proteins or bcap73 targets as, for example, downstream elements of a bcap73-mediated signaling pathway. Alternatively, such bcap73-binding proteins are likely to be bcap73 inhibitors.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a bcap73 protein is fused to a gene encoding the DNA binding domain of a known transcription factor (*e.g.*, GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming a bcap73-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (*e.g.*, LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the bcap73 protein.

In another aspect, the invention pertains to a combination of two or more of the assays described herein. For example, a modulating agent can be identified using a cell-based or a cell free assay, and the ability of the agent to modulate the activity of a bcap73 protein can be confirmed *in vivo*, *e.g.*, in an animal, such as an animal model for a cardiovascular disorder, *e.g.*, a model of cardiac myocyte hypertrophy or a model for atherosclerosis. By further example, such an animal model can include one for angiogenesis

(*e.g.* tumor induced), or an animal model which encompasses aspects of epidermal wounds (*e.g.* burns or surgical wounds).

This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (*e.g.*, a bcap73 modulating agent, an antisense bcap73 nucleic acid molecule, a bcap73-specific antibody, or a bcap73-binding partner) can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

B. Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. These applications are described in the subsections below.

1. Chromosome Mapping

Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the bcap73 nucleotide sequences, described herein, can be used to map the location of the bcap73 genes on a chromosome. The mapping of the bcap73 sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

Briefly, bcap73 genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the bcap73 nucleotide sequences. Computer analysis of the bcap73 sequences can be used to predict primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the bcap73 sequences will yield an amplified fragment.

Somatic cell hybrids are prepared by fusing somatic cells from different mammals (*e.g.*, human and mouse cells). As hybrids of human and mouse cells grow and divide, they

gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but human cells can, the one human chromosome that contains the gene encoding the needed enzyme, will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. (D'Eustachio P. *et al.* (1983) *Science* 220:919-924). Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.

PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the bcap73 nucleotide sequences to design oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes. Other mapping strategies which can similarly be used to map a bcap73 sequence to its chromosome include *in situ* hybridization (described in Fan, Y. *et al.* (1990) *Proc. Natl. Acad. Sci. USA*, 87:6223-27), pre-screening with labeled flow-sorted chromosomes, and pre-selection by hybridization to chromosome specific cDNA libraries.

Fluorescence *in situ* hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical such as colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases will suffice to get good results at a reasonable amount of time. For a review of this technique, see Verma *et al.*, Human Chromosomes: A Manual of Basic Techniques (Pergamon Press, New York 1988).

Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. (Such

data are found, for example, in V. McKusick, Mendelian Inheritance in Man, available on-line through Johns Hopkins University Welch Medical Library). The relationship between a gene and a disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, for example,

5 Egeland, J. *et al.* (1987) *Nature*, 325:783-787.

Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the *bcap73* gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of
10 affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

15

2. Tissue Typing

20 The *bcap73* sequences of the present invention can also be used to identify individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for
25 identification. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The sequences of the present invention are useful as additional DNA markers for RFLP (described in U.S. Patent 5,272,057).

Furthermore, the sequences of the present invention can be used to provide an
30 alternative technique which determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the *bcap73* nucleotide sequences described herein can be used to prepare two PCR primers from the 5' and 3' ends of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner,
35 can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the present invention can be used to obtain such identification sequences from individuals and from tissue. The *bcap73* nucleotide sequences of the invention uniquely represent portions of the human

genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequence of SEQ ID NO: 1 can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers which each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as that of SEQ ID NO: 3 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

If a panel of reagents from bcap73 nucleotide sequences described herein is used to generate a unique identification database for an individual, those same reagents can later be used to identify tissue from that individual. Using the unique identification database, positive identification of the individual, living or dead, can be made from extremely small tissue samples.

3. Use of Partial bcap73 Sequences in Forensic Biology

DNA-based identification techniques can also be used in forensic biology. Forensic biology is a scientific field employing genetic typing of biological evidence found at a crime scene as a means for positively identifying, for example, a perpetrator of a crime. To make such an identification, PCR technology can be used to amplify DNA sequences taken from very small biological samples such as tissues, *e.g.*, hair or skin, or body fluids, *e.g.*, blood, saliva, or semen found at a crime scene. The amplified sequence can then be compared to a standard, thereby allowing identification of the origin of the biological sample.

The sequences of the present invention can be used to provide polynucleotide reagents, *e.g.*, PCR primers, targeted to specific loci in the human genome, which can enhance the reliability of DNA-based forensic identifications by, for example, providing another "identification marker" (*i.e.* another DNA sequence that is unique to a particular individual). As mentioned above, actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated fragments. Sequences targeted to noncoding regions of SEQ ID NO: 1 are particularly appropriate for this use as greater numbers of polymorphisms occur in the noncoding regions, making it easier to differentiate individuals using this technique. Examples of polynucleotide reagents include the bcap73 nucleotide sequences or portions thereof, *e.g.*, fragments derived from the noncoding regions of SEQ ID NO: 1, having a length of at least 20 bases, preferably at least 30 bases.

The bcap73 nucleotide sequences described herein can further be used to provide polynucleotide reagents, *e.g.*, labeled or labelable probes which can be used in, for example, an *in situ* hybridization technique, to identify a specific tissue, *e.g.*, brain tissue. This can be very useful in cases where a forensic pathologist is presented with a tissue of unknown origin. Panels of such bcap73 probes can be used to identify tissue by species and/or by organ type.

In a similar fashion, these reagents, *e.g.*, bcap73 primers or probes can be used to screen tissue culture for contamination (*i.e.* screen for the presence of a mixture of different types of cells in a culture).

C. Predictive Medicine:

The present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the present invention relates to diagnostic assays for determining bcap73 protein and/or nucleic acid expression as well as bcap73 activity, in the context of a biological sample (*e.g.*, blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant or unwanted bcap73 expression or activity. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with bcap73 protein, nucleic acid expression or activity. For example, mutations in a bcap73 gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with bcap73 protein, nucleic acid expression or activity. In a preferred embodiment, such a disorder includes cardiovascular diseases, disorders, or states involving the cardiovascular system, *e.g.*, the heart, the blood vessels, and/or the blood.

Another aspect of the invention pertains to monitoring the influence of agents (*e.g.*, drugs, compounds) on the expression or activity of bcap73 in clinical trials.

These and other agents are described in further detail in the following sections.

1. Diagnostic Assays

An exemplary method for detecting the presence or absence of bcap73 protein or nucleic acid in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting bcap73 protein or nucleic acid (*e.g.*, mRNA, or genomic DNA) that encodes bcap73 protein such that the presence of bcap73 protein or nucleic acid is detected in the biological sample. A preferred agent for detecting bcap73 mRNA or genomic DNA is a

labeled nucleic acid probe capable of hybridizing to bcap73 mRNA or genomic DNA. The nucleic acid probe can be, for example, the bcap73 nucleic acid set forth in SEQ ID NO: 1 or 3, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to bcap73 mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

A preferred agent for detecting bcap73 protein is an antibody capable of binding to bcap73 protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (*e.g.*, Fab or F(ab')₂) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (*i.e.*, physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect bcap73 mRNA, protein, or genomic DNA in a biological sample *in vitro* as well as *in vivo*. For example, *in vitro* techniques for detection of bcap73 mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of bcap73 protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. *In vitro* techniques for detection of bcap73 genomic DNA include Southern hybridizations. Furthermore, *in vivo* techniques for detection of bcap73 protein include introducing into a subject a labeled anti-bcap73 antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a serum sample isolated by conventional means from a subject.

In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting bcap73 protein, mRNA, or genomic DNA, such that the presence of bcap73 protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of bcap73 protein, mRNA or genomic DNA in the control sample with the presence of bcap73 protein, mRNA or genomic DNA in the test sample.

The invention also encompasses kits for detecting the presence of bcap73 in a biological sample. For example, the kit can comprise a labeled compound or agent capable of detecting bcap73 protein or mRNA in a biological sample; means for determining the amount of bcap73 in the sample; and means for comparing the amount of bcap73 in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect bcap73 protein or nucleic acid.

2. Prognostic Assays

The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant or unwanted bcap73 expression or activity. As used herein, the term "aberrant" includes a bcap73 expression or activity which deviates from the wild type bcap73 expression or activity. Aberrant expression or activity includes increased or decreased expression or activity, as well as expression or activity which does not follow the wild type developmental pattern of expression or the subcellular pattern of expression or wildtype activity which is either insufficient or overabundant for therapeutic effect. For example, aberrant bcap73 expression or activity is intended to include the cases in which a mutation in the bcap73 gene causes the bcap73 gene to be under-expressed or over-expressed and situations in which such mutations result in a non-functional bcap73 protein or a protein which does not function in a wild-type fashion, *e.g.*, a protein which does not interact with a bcap73 substrate, *e.g.*, an actin molecule or an ezrin molecule, or one which interacts with a non-bcap73 substrate, *e.g.* a non-actin molecule or a non-ezrin molecule. As used herein, the term "unwanted" includes an unwanted phenomenon involved in a biological response such as cellular proliferation. For example, the term unwanted includes a bcap73 expression or activity which is undesirable in a subject.

The assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with a misregulation in bcap73 protein activity or nucleic acid expression, such as a proliferative disorder, a differentiative disorder, a pain disorder, or a cardiovascular disorder. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disorder associated with a misregulation in bcap73 protein activity or nucleic acid expression, such as a proliferative disorder. Thus, the present invention provides a method for identifying a disease or disorder associated with aberrant or unwanted bcap73 expression or activity in which a test sample is obtained from a subject and bcap73 protein or nucleic acid (*e.g.*, mRNA or genomic DNA) is detected, wherein the presence of bcap73 protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant or unwanted bcap73 expression or activity. As

used herein, a "test sample" refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (*e.g.*, serum), cell sample, or tissue.

Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (*e.g.*, an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant or unwanted bcap73 expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a proliferative disorder, a differentiative disorder, or a pain disorder. Thus, the present invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant or unwanted bcap73 expression or activity in which a test sample is obtained and bcap73 protein or nucleic acid expression or activity is detected (*e.g.*, wherein the abundance of bcap73 protein or nucleic acid expression or activity is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant or unwanted bcap73 expression or activity).

The methods of the invention can also be used to detect genetic alterations in a bcap73 gene, thereby determining if a subject with the altered gene is at risk for a disorder characterized by misregulation in bcap73 protein activity or nucleic acid expression, such as a proliferative disorder. In preferred embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic alteration characterized by at least one of an alteration affecting the integrity of a gene encoding a bcap73-protein, or the mis-expression of the bcap73 gene. For example, such genetic alterations can be detected by ascertaining the existence of at least one of 1) a deletion of one or more nucleotides from a bcap73 gene; 2) an addition of one or more nucleotides to a bcap73 gene; 3) a substitution of one or more nucleotides of a bcap73 gene, 4) a chromosomal rearrangement of a bcap73 gene; 5) an alteration in the level of a messenger RNA transcript of a bcap73 gene, 6) aberrant modification of a bcap73 gene, such as of the methylation pattern of the genomic DNA, 7) the presence of a non-wild type splicing pattern of a messenger RNA transcript of a bcap73 gene, 8) a non-wild type level of a bcap73-protein, 9) allelic loss of a bcap73 gene, and 10) inappropriate post-translational modification of a bcap73-protein. As described herein, there are a large number of assays known in the art which can be used for detecting alterations in a bcap73 gene. A preferred biological sample is a tissue or serum sample isolated by conventional means from a subject.

In certain embodiments, detection of the alteration involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, *e.g.*, U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, *e.g.*, Landegran *et al.* (1988) *Science* 241:1077-1080; and Nakazawa *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:360-364), the latter of which can be particularly useful for detecting point mutations in the bcap73-gene (see Abravaya *et al.* (1995) *Nucleic Acids Res.* 23:675-

682). This method can include the steps of collecting a sample of cells from a subject, isolating nucleic acid (*e.g.*, genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a bcap73 gene under conditions such that hybridization and amplification of the bcap73-
5 gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

10 Alternative amplification methods include: self sustained sequence replication (Guatelli, J.C. *et al.*, (1990) *Proc. Natl. Acad. Sci. USA* 87:1874-1878), transcriptional amplification system (Kwoh, D.Y. *et al.*, (1989) *Proc. Natl. Acad. Sci. USA* 86:1173-1177), Q-Beta Replicase (Lizardi, P.M. *et al.* (1988) *Bio-Technology* 6:1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using
15 techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

In an alternative embodiment, mutations in a bcap73 gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and
20 control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, for example, U.S. Patent No. 5,498,531) can be used to score for the presence of specific
25 mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in bcap73 can be identified by hybridizing a sample and control nucleic acids, *e.g.*, DNA or RNA, to high density arrays containing hundreds or thousands of oligonucleotides probes (Cronin, M.T. *et al.* (1996) *Human Mutation* 7: 244-255; Kozal, M.J. *et al.* (1996) *Nature Medicine* 2: 753-759). For example,
30 genetic mutations in bcap73 can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, M.T. *et al. supra*. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This
35 step is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the bcap73 gene and detect mutations by comparing the sequence of the sample bcap73 with the corresponding wild-type (control) sequence.

Examples of sequencing reactions include those based on techniques developed by Maxam and Gilbert ((1977) *Proc. Natl. Acad. Sci. USA* 74:560) or Sanger ((1977) *Proc. Natl. Acad. Sci. USA* 74:5463). It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays ((1995) *Biotechniques* 19:448), including sequencing by mass spectrometry (see, *e.g.*, PCT International Publication No. WO 94/16101; Cohen *et al.* (1996) *Adv. Chromatogr.* 36:127-162; and Griffin *et al.* (1993) *Appl. Biochem. Biotechnol.* 38:147-159).

Other methods for detecting mutations in the bcap73 gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes (Myers *et al.* (1985) *Science* 230:1242). In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type bcap73 sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent which cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S1 nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, for example, Cotton *et al.* (1988) *Proc. Natl Acad Sci USA* 85:4397; Saleeba *et al.* (1992) *Methods Enzymol.* 217:286-295. In a preferred embodiment, the control DNA or RNA can be labeled for detection.

In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in bcap73 cDNAs obtained from samples of cells. For example, the mutY enzyme of *E. coli* cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches (Hsu *et al.* (1994) *Carcinogenesis* 15:1657-1662). According to an exemplary embodiment, a probe based on a bcap73 sequence, *e.g.*, a wild-type bcap73 sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, for example, U.S. Patent No. 5,459,039.

In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in bcap73 genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids (orita *et al.* (1989) *Proc Natl. Acad. Sci USA*: 86:2766, see also Cotton (1993) *Mutat. Res.* 285:125-144; and Hayashi (1992) *Genet. Anal. Tech. Appl.* 9:73-79). Single-stranded DNA fragments of sample and control bcap73 nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In a preferred embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen *et al.* (1991) *Trends Genet* 7:5).

In yet another embodiment the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers *et al.* (1985) *Nature* 313:495). When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA (Rosenbaum and Reissner (1987) *Biophys Chem* 265:12753).

Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions which permit hybridization only if a perfect match is found (Saiki *et al.* (1986) *Nature* 324:163); Saiki *et al.* (1989) *Proc. Natl Acad. Sci USA* 86:6230). Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

Alternatively, allele specific amplification technology which depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization) (Gibbs *et al.* (1989) *Nucleic Acids Res.* 17:2437-2448) or at the extreme 3' end of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (Prossner (1993) *Tibtech* 11:238). In addition it may be desirable to introduce a novel restriction site in

the region of the mutation to create cleavage-based detection (Gasparini *et al.* (1992) *Mol. Cell Probes* 6:1). It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification (Barany (1991) *Proc. Natl. Acad. Sci USA* 88:189). In such cases, ligation will occur only if there is a perfect match at the 3' end of the 5' sequence making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, *e.g.*, in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a bcap73 gene.

Furthermore, any cell type or tissue in which bcap73 is expressed may be utilized in the prognostic assays described herein.

3. Monitoring of Effects During Clinical Trials

Monitoring the influence of agents (*e.g.*, drugs) on the expression or activity of a bcap73 protein (*e.g.*, the modulation of cell proliferation and/or migration) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase bcap73 gene expression, protein levels, or upregulate bcap73 activity, can be monitored in clinical trials of subjects exhibiting decreased bcap73 gene expression, protein levels, or down-regulated bcap73 activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease bcap73 gene expression, protein levels, or down-regulate bcap73 activity, can be monitored in clinical trials of subjects exhibiting increased bcap73 gene expression, protein levels, or up-regulated bcap73 activity. In such clinical trials, the expression or activity of a bcap73 gene, and preferably, other genes that have been implicated in, for example, a bcap73-associated disorder can be used as a "read out" or markers of the phenotype of a particular cell.

For example, and not by way of limitation, genes, including bcap73, that are modulated in cells by treatment with an agent (*e.g.*, compound, drug or small molecule) which modulates bcap73 activity (*e.g.*, identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on bcap73-associated disorders (*e.g.*, disorders characterized by deregulated cell proliferation and/or migration), for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of bcap73 and other genes implicated in the bcap73-associated disorder, respectively. The levels of gene expression (*e.g.*, a gene expression pattern) can be quantified by northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by

measuring the levels of activity of bcap73 or other genes. In this way, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during treatment of the individual with the agent.

5 In a preferred embodiment, the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (*e.g.*, an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) including the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting
10 the level of expression of a bcap73 protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the bcap73 protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the bcap73 protein, mRNA, or genomic DNA in the pre-administration sample
15 with the bcap73 protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of bcap73 to higher levels than detected, *i.e.*, to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease
20 expression or activity of bcap73 to lower levels than detected, *i.e.* to decrease the effectiveness of the agent. According to such an embodiment, bcap73 expression or activity may be used as an indicator of the effectiveness of an agent, even in the absence of an observable phenotypic response.

25 D. Methods of Treatment:

The present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant or unwanted bcap73 expression or activity, *e.g.* a cellular disorder, a cytoskeletal disorder, a motility disorder, or a tissue-repair disorder. In a preferred embodiment, such a
30 disorder includes cardiovascular diseases, disorders, or states involving the cardiovascular system, *e.g.*, the heart, the blood vessels, and/or the blood. In a further preferred embodiment, such a disorder includes diseases, disorders, or states involving angiogenesis (*e.g.* tumor induced). In another preferred embodiment, such a disorder includes diseases, disorders, or states related to wound (*e.g.* epidermal wounds, burns, or surgical wounds).
35 With regards to both prophylactic and therapeutic methods of treatment, such treatments may be specifically tailored or modified, based on knowledge obtained from the field of pharmacogenomics. "Pharmacogenomics", as used herein, refers to the application of genomics technologies such as gene sequencing, statistical genetics, and gene expression

analysis to drugs in clinical development and on the market. More specifically, the term refers the study of how a patient's genes determine his or her response to a drug (*e.g.*, a patient's "drug response phenotype", or "drug response genotype".) Thus, another aspect of the invention provides methods for tailoring an individual's prophylactic or therapeutic treatment with either the β CAP73 molecules of the present invention or β CAP73 modulators according to that individual's drug response genotype. Pharmacogenomics allows a clinician or physician to target prophylactic or therapeutic treatments to patients who will most benefit from the treatment and to avoid treatment of patients who will experience toxic drug-related side effects.

1. Prophylactic Methods

In one aspect, the invention provides a method for preventing in a subject, a disease or condition associated with an aberrant or unwanted β CAP73 expression or activity, by administering to the subject a β CAP73 or an agent which modulates β CAP73 expression or at least one β CAP73 activity. Subjects at risk for a disease which is caused or contributed to by aberrant or unwanted β CAP73 expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the β CAP73 aberrance, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending on the type of β CAP73 aberrance, for example, a β CAP73, β CAP73 agonist or β CAP73 antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein.

2. Therapeutic Methods

Another aspect of the invention pertains to methods of modulating β CAP73 expression or activity for therapeutic purposes. Accordingly, in an exemplary embodiment, the modulatory method of the invention involves contacting a cell with a β CAP73 or agent that modulates one or more of the activities of β CAP73 protein activity associated with the cell. An agent that modulates β CAP73 protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring target molecule of a β CAP73 protein (*e.g.*, a β CAP73 substrate), a β CAP73 antibody, a β CAP73 agonist or antagonist, a peptidomimetic of a β CAP73 agonist or antagonist, or other small molecule. In one embodiment, the agent stimulates one or more β CAP73 activities. Examples of such stimulatory agents include active β CAP73 protein and a nucleic acid molecule encoding β CAP73 that has been introduced into the cell. In another embodiment, the agent inhibits one or more β CAP73 activities. Examples of such inhibitory agents include antisense β CAP73 nucleic acid molecules, anti- β CAP73 antibodies, and β CAP73 inhibitors. These modulatory methods can be performed *in vitro* (*e.g.*, by culturing the cell with the agent) or,

alternatively, *in vivo* (e.g., by administering the agent to a subject). As such, the present invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant or unwanted expression or activity of a β CAP73 protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., upregulates or downregulates) β CAP73 expression or activity. In another embodiment, the method involves administering a β CAP73 protein or nucleic acid molecule as therapy to compensate for reduced, aberrant, or unwanted β CAP73 expression or activity. Stimulation of β CAP73 activity is desirable in situations in which β CAP73 is abnormally down-regulated and/or in which increased β CAP73 activity is likely to have a beneficial effect. Likewise, inhibition of β CAP73 activity is desirable in situations in which β CAP73 is abnormally up-regulated and/or in which decreased β CAP73 activity is likely to have a beneficial effect.

3. Pharmacogenomics

The β CAP73 molecules of the present invention, as well as agents, or modulators which have a stimulatory or inhibitory effect on β CAP73 activity (e.g., β CAP73 gene expression) as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) β CAP73-associated disorders (e.g., proliferative disorders) associated with aberrant or unwanted β CAP73 activity. In conjunction with such treatment, pharmacogenomics (*i.e.*, the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, a physician or clinician may consider applying knowledge obtained in relevant pharmacogenomics studies in determining whether to administer a β CAP73 molecule or β CAP73 modulator as well as tailoring the dosage and/or therapeutic regimen of treatment with a β CAP73 molecule or β CAP73 modulator.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, for example, Eichelbaum, M. *et al.* (1996) *Clin. Exp. Pharmacol. Physiol.* 23(10-11): 983-985 and Linder, M.W. *et al.* (1997) *Clin. Chem.* 43(2):254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare genetic defects or as naturally-occurring polymorphisms. For example, glucose-6-phosphate dehydrogenase deficiency (G6PD) is a common inherited enzymopathy in which the main clinical

complication is haemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

One pharmacogenomics approach to identifying genes that predict drug response, known as "a genome-wide association", relies primarily on a high-resolution map of the human genome consisting of already known gene-related markers (*e.g.*, a "bi-allelic" gene marker map which consists of 60,000-100,000 polymorphic or variable sites on the human genome, each of which has two variants.) Such a high-resolution genetic map can be compared to a map of the genome of each of a statistically significant number of patients taking part in a Phase II/III drug trial to identify markers associated with a particular observed drug response or side effect. Alternatively, such a high resolution map can be generated from a combination of some ten-million known single nucleotide polymorphisms (SNPs) in the human genome. As used herein, a "SNP" is a common alteration that occurs in a single nucleotide base in a stretch of DNA. For example, a SNP may occur once per every 1000 bases of DNA. A SNP may be involved in a disease process, however, the vast majority may not be disease-associated. Given a genetic map based on the occurrence of such SNPs, individuals can be grouped into genetic categories depending on a particular pattern of SNPs in their individual genome. In such a manner, treatment regimens can be tailored to groups of genetically similar individuals, taking into account traits that may be common among such genetically similar individuals.

Alternatively, a method termed the "candidate gene approach", can be utilized to identify genes that predict drug response. According to this method, if a gene that encodes a drugs target is known (*e.g.*, a bcap73 protein of the present invention), all common variants of that gene can be fairly easily identified in the population and it can be determined if having one version of the gene versus another is associated with a particular drug response.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (*e.g.*, N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. The other extreme

are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

Alternatively, a method termed the "gene expression profiling", can be utilized to identify genes that predict drug response. For example, the gene expression of an animal dosed with a drug (*e.g.*, a β CAP73 molecule or β CAP73 modulator of the present invention) can give an indication whether gene pathways related to toxicity have been turned on.

Information generated from more than one of the above pharmacogenomics approaches can be used to determine appropriate dosage and treatment regimens for prophylactic or therapeutic treatment an individual. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a β cap73 molecule or β CAP73 modulator, such as a modulator identified by one of the exemplary screening assays described herein.

15

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application, as well as the Figures and the Sequence Listing, are incorporated herein by reference.

20

EXAMPLES

Example 1: Identification and Characterization of β cap73 cDNAs

25

Purification of β cap73 protein from bovine retinal pericytes or bovine platelets

A Triton X-100 soluble lysate from bovine retinal pericytes or bovine platelets can be enriched for β CAP 73 protein by using ion-exchange purification. The lysate is first applied to SP-sepharose under ionic strength conditions for β CAP 73 to bind to the resin. After washing contaminating proteins away, a fraction containing β CAP 73 protein can be eluted between 185 and 230 mM NaCl (see Figure 2, lane B). A second ion-exchange chromatography with DEAE-sepharose is able to purify the protein further. After loading and washing steps analogous to those outlined above, the β CAP 73 protein is able to be eluted between 70 and 80mM NaCl. A β CAP 73 protein obtained in this manner can be greater than 90% pure (see Figure 2, lane C).

35

Isolation and cloning of the bovine β CAP 73 cDNA

The invention is based, at least in part, on the discovery of a bovine gene encoding a novel protein, referred to herein as β CAP 73. Total RNA was harvested from bovine endothelial cells (ECs) that were crawling in response to mechanical injury and purified as previously described (Hooock et al. 1991). 5 μ g of polyA⁺ RNA isolated using PolyAtract (Promega) served as template for expression library construction using the λ ZAPII library kit from Stratagene, following manufacturer protocols. Average insert size was 1.4 kb (+/- 0.5), with a range of 600 bp to 2.5 kb, as assessed by mass excision of the library and analysis of 10 randomly chosen colonies. The number of individual clones in the library was greater than 1×10^6 .

To identify the β CAP73 cDNA, 2.1×10^5 plaques were plated on 150 mm NZY plates at a density of 2.3×10^4 plaques/plate. Replica nitrocellulose filters were washed with 25 mL per filter of TBS-Tween (TBST, 20 mM Tris, pH. 7.5, 0.9% NaCl, 0.05% Tween-20) prior to blocking with 5% milk in TBST. Washed and blocked filters were probed with anti- β CAP73 mAb as follows. Concentrated hybridoma cultured supernatant containing 30 μ g/mL anti- β CAP73 IgM was pre-incubated with 0.25 mg/mL XL1-Blue bacterial lysate for 1 h at RT, rocking. The blocked anti- β CAP73 IgM was then diluted 1:3 with TBST and 5% milk TBST to reach a final concentration of 10 μ g/mL antibody and 2.5% milk. The filters were incubated overnight at 4°C, rocking. After extensive washing, the filters were incubated with HRP-labeled secondary antibody for 1 h at RT, washed again, and 27 positive plaques were identified. The positives were collected into two pools and rescreened. After the second round of screening, one positive plaque remained that was plaque pure after re-plating and re-probing with the anti- β CAP73 mAb. The β CAP73 cDNA-containing plasmid was excised out of the λ arms using ExAssist helper bacteriophage (Stratagene) and sequenced. The novel clone contained a 2.5 kb open reading frame that extended to the 5' end of the clone. To obtain the remainder of the β CAP73 cDNA, 5' RACE (rapid amplification of cDNA ends) was implemented.

5'RACE

5'RACE reagents were obtained from Gibco-BRL, and procedures were performed as described by the manufacturer with one modification: the reverse transcription (rev) reaction was carried out for 30 min at 50°C instead of 42°C. β CAP73 gene-specific, anti-sense primer pairs that were used in the reactions are as follows: RACE-1, rev:

5'GCTCTAATCTGCTCTTGAGC (SEQ ID NO:5), PCR:

5'CTAGTCGACTGTTCTCTGGTTTGACGTG (SEQ ID NO:6); RACE-2, rev:

TCAGCCTGTGGTTCCCAGTGG (SEQ ID NO:7), PCR:

TGTCAGGTGCTCTTTCAAGGC (SEQ ID NO:8); RACE-3, rev:

5'GTAGCTGTAAACCATTGACT (SEQ ID NO:9), PCR:

5'ATATTCTCTGTTCTTGCTGA (SEQ ID NO:10); RACE-4, rev:

5'CTAGCTTGCCTGGATTGACTC (SEQ ID NO:11), PCR:

5'TTTAGCAAGGATTGAGGACAC (SEQ ID NO:12). The 5'RACE products were purified and concentrated using Qiaquick columns (Qiagen) and ligated into pGEM-TEasy vectors (Promega). New sequences from each round of 5'RACE were compared using
5 MacDNAsis software to resolve any PCR-generated errors. At least 6 individual clones for each round of 5'RACE were analyzed and sequenced. Each round of 5'RACE yielded 400-800 bp of new cDNA.

The sequence of the entire clone was determined to be 4736 nucleotides in length. This sequence is SEQ IN NO:1 and is shown in Figures 4-1 through 4-8. An open reading
10 frame (ORF) was identified from nucleotides 392 to 4597, which codes for a deduced amino acid sequence of 1401 residues. The full cDNA with its corresponding ORF amino acid sequence is shown in Figures 4-1 through 4-8.

Analysis of the bovine β CAP73 molecules

15 A BLAST search (Altschul et al. (1990) *J. Mol. Biol.* 215:403) of the nucleotide sequence of bovine β CAP 73 has revealed that separate internal regions of the β CAP 73 cDNA are significantly similar to *C. familiaris* mRNA sequence for C3VS (GenBank Accession No. X99145), a Tentative Human Consensus (THC) Contiguous Sequence from the TIGR (Accession Nos. THC244788, THC186491, THC186491, THC213238), and the
20 human KIAA1561 protein (Accession No. AB046781).

Tissue distribution of β CAP 73 mRNA

This example describes the tissue distribution of β CAP 73 transporter mRNA, as can be determined by Northern blot hybridization and *in situ* hybridization.

25 Northern blot hybridizations with the various RNA samples are performed under standard conditions and washed under stringent conditions, i.e., 0.2XSSC at 65°C. The DNA probe is radioactively labeled with 32 P-dCTP using the Prime-It kit (Stratagene, La Jolla, CA) according to the instructions of the supplier. Filters containing human mRNA (MultiTissue Northern I and MultiTissue Northern II from Clontech, Palo Alto, CA) are
30 probed in ExpressHyb hybridization solution (Clontech) and washed at high stringency according to manufacturer's recommendations. Figure 5 shows the results of such an analysis, with β CAP 73 mRNA detected predominantly in skeletal muscle as well as brain and heart.

To detect β CAP73 mRNA, 1 ug of polyA EC RNA from was separated in a 1.2%
35 agarose-formaldehyde bed gel, transferred to nylon membrane (Schleicher and Schuell) by capillary transfer and UV crosslinked to the membrane. The blot was incubated in pre-hybridization solution (50% formamide, 5X SSPE, 5X Denhardt's, 1% SDS, 10% dextran sulfate, 100 μ g/mL polyA and 100 μ g/mL salmon sperm DNA) for at least 3 h at 42°C.

Nick-translated, [^{32}P]-labeled probe was made from plasmid containing the library clone (nt 2303-4719 of the βCAP73 cDNA; [$\alpha\text{-}^{32}\text{P}$] dCTP from ICN, DNase I and DNA polymerase I from Gibco-BRL). The probe was mixed at 1×10^6 cpm/mL into the pre-hybridization solution and incubated with the blot for 16 h at 42°C . The blot was washed first in 1XSSC (150 mM NaCl, 15 mM sodium citrate, pH 7.0), 0.1% SDS for 15 min at room temperature (RT), followed by a second wash in 0.25XSSC, 0.1% SDS for 15 min at RT. The blots were exposed to autoradiographic film (Kodak) at -80°C for 24 h prior to development.

For *in situ* analysis, various tissue samples are obtained from brain, skeletal muscle, cardiovascular tissue, or other tissues and are first frozen on dry ice. Ten-micrometer-thick coronal sections of the tissues are postfixed with 4% formaldehyde in DEPC treated 1X phosphate-buffered saline at room temperature for 10 minutes before being rinsed twice in DEPC 1X phosphate-buffered saline and once in 0.1 M triethanolamine-HCl (pH 8.0). Following incubation in 0.25% acetic anhydride-0.1 M triethanolamine-HCl for 10 minutes, sections are rinsed in DEPC 2X SSC (1X SSC is 0.15M NaCl plus 0.015M sodium citrate). Tissue is then dehydrated through a series of ethanol washes, incubated in 100% chloroform for 5 minutes, and then rinsed in 100% ethanol for 1 minute and 95% ethanol for 1 minute and allowed to air dry.

Hybridizations are performed with ^{35}S -radiolabeled (5×10^7 cpm/mL) cRNA probes. Probes are incubated in the presence of a solution containing 600 mM NaCl, 10 mM Tris (pH 7.5), 1 mM EDTA, 0.01% sheared salmon sperm DNA, 0.01% yeast tRNA, 0.05% yeast total RNA type X1, 1X Denhardt's solution, 50% formamide, 10% dextran sulfate, 100 mM dithiothreitol, 0.1% sodium dodecyl sulfate (SDS), and 0.1% sodium thiosulfate for 18 hours at 55°C .

After hybridization, slides are washed with 2X SSC. Sections are then sequentially incubated at 37°C in TNE (a solution containing 10 mM Tris-HCl (pH 7.6), 500 mM NaCl, and 1 mM EDTA), for 10 minutes, in TNE with 10 μg of RNase A per mL for 30 minutes, and finally in TNE for 10 minutes. Slides are then rinsed with 2X SSC at room temperature, washed with 2X SSC at 50°C for 1 hour, washed with 0.2X SSC at 55°C for 1 hour, and 0.2X SSC at 60°C for 1 hour. Sections are then dehydrated rapidly through serial ethanol-0.3 M sodium acetate concentrations before being air dried and exposed to Kodak Biomax MR scientific imaging film for 24 hours and subsequently dipped in NB-2 photoemulsion and exposed at 4°C for 7 days before being developed and counter stained.

To explore the relative abundance and tissue distribution of βCAP73 , Northern analysis was performed. A probe was made to nt 3502-4719, a region of βCAP73 that is highly homologous to human KIAA1561 (Accession No. AB046781). Hybridization of human tissues with radiolabeled probe revealed expression of an approximately 5 kb transcript in all tissues tested. Stripping and re-probing of the blot with β -actin probe allowed the normalization of βCAP73 expression. The strongest expression occurred in

skeletal muscle followed by heart, with relative expression levels of 6.3 (arbitrary units) and 1.7, respectively. Relative expression in the other tissues tested ranged from 0.63 in kidney to 0.083 in lung. Lack of expression in brain was due to the very low amount of mRNA analyzed, evidenced by the low β -actin signal.

Example 2: Recombinant Expression of β CAP 73 in Bacterial Cells

In this example, β CAP 73 was expressed as a recombinant glutathione-S-transferase (GST) fusion polypeptide in *E. coli* and the fusion polypeptide was isolated and characterized.

GST- β CAP73 domains

Bacterial glutathione-S-transferase (GST) fusion constructs were made in the pGEX-3X vector, which contains a Factor Xa site to cleave the GST moiety from the recombinant β CAP73 domains (Pharmacia). Inserts encoding for β CAP73-F and β CAP73-C (see Figure 2A) were made by PCR using sequence specific primers that generated restriction endonuclease sites for in-frame ligation into pGEX-3X. The β CAP73 library clone was used as the target for the PCR reactions. The primer pairs used are as follows: β CAP73-F forward) 5'CGGGATCCCCGTGGAAAGAGAATATGAAAGATCA (SEQ ID NO:13), β CAP73-F reverse) 5'CGGGATCCCCGGCACACGAGCCCCCTGCCG (SEQ ID NO:14); β CAP73-C forward) 5'CGGGATCCCCAATTCTTATGAAACAGAAAGAGCA (SEQ ID NO:15), β CAP73-C reverse) 5'CGGGATCCCCGGCACACGAGCCCCCTGCCG (SEQ ID NO:16). The β CAP73-N construct was generated by digestion of the library clone in pBluescript with EcoRI to release the β CAP73-N fragment. The fragment was then ligated in-frame into the pGEX-3X expression vector. All constructs were re-sequenced to assure that no mutations were generated during PCR amplification.

Expression and Purification of GST- β CAP73 domains

Bacterial expression was performed basically according to the manufacturer's protocol, except that expression was induced with 0.1 mM IPTG for 2 h at 28°C instead of 37°C. After induction, the cells were pelleted and stored at -80°C.

The β CAP73 domains were purified according to manufacturer protocols (Pharmacia). Purified GST- β CAP73 fusion products bound to glutathione-Sepharose were exchanged into Factor Xa cleavage buffer (50 mM Tris, pH 7.5, 150 mM NaCl, and 1 mM CaCl_2) and treated with Factor Xa at a final concentration of 0.25 U/mL of matrix for 2 h at RT, rotating. β CAP73 domains relieved of the GST moiety were then collected as flowthrough. Almost 90% of the β CAP73 domains were recovered compared to the total GST- β CAP73 that was purified. Typical yield for GST- β CAP73-F and GST- β CAP73-N

fusion proteins was 0.5 mg from 100 mL of culture. The GST- β CAP73-C construct typically yielded <0.5 μ g protein from 100 mL of starting culture.

Example 3: Recombinant β CAP73 Expression

5

Full-length β CAP73-His

The full-length β CAP73-His mammalian expression plasmid was created as follows. First, the 5'RACE fragments and the library fragment were ligated together by PCR-mediated ligation. Forward primers were made to the 5' ends of all the fragments of the β CAP73 clone. The forward primer made to the RACE-4 fragment also contained a KpnI site, underlined in the sequence. The primer sequences are RACE-1)
5'GAACTGGCTCACAAGGTGGC (SEQ ID NO:17), RACE-2)
5'GGTGACAATCTGGACATTCTAA (SEQ ID NO:18), RACE-3)
5'TCCTGTCTATGATGAGCTGTTG (SEQ ID NO:19), RACE-4)
15 5'GGGGTACCAAGTGTGAGGCGGCAGGAT (SEQ ID NO:20). The following reverse primer was made for the 3' most fragment (original library fragment) that contained bases encoding for six histidines (in parentheses), a termination codon (in bold), and XbaI site (underlined) for ligation into pcDNA3 (Invitrogen):
5'GCTCTAGACTA(GTGATGGTGATGGTGATG) GCACACGAGCCCCTGCCG (SEQ
20 ID NO:21). The reverse primers against the RACE fragments were the same as the PCR primers used to generate the RACE clones. β CAP73 clone fragments were ligated by putting the following into a PCR reaction: 1.5×10^{-14} moles each of the gel purified library fragment and RACE1 fragment, forward primer to the RACE-1 fragment and reverse primer for the library fragment, 0.2 mM dNTPs, 1.5 mM $MgCl_2$, 0.25 U/ μ l Tli DNA polymerase
25 (Promega), and 1X Tli polymerase buffer. PCR cycles were as follows: 5 cycles of denaturation at 95°C, 1 min, annealing and extension at 72°C for 5 min, 20 cycles of denaturation at 95°C, 1 min, annealing at 55°C for 30 s, and extension at 72°C for 5 min. RACE fragments 2 and 3 were ligated using the RACE-3 forward primer and the RACE-2 PCR reverse primer in the same DNA ligation/amplification reaction as just described. The
30 RACE 2/3 fragment was then ligated to the RACE-4 fragment in the same manner, except the primers used in the reaction were the RACE-4 forward and the RACE-2 PCR reverse. Finally the RACE2/3/4 fragment was ligated to the RACE1/library fragment to generate the final 4.7 kb insert by using the RACE-4 forward primer and the library fragment reverse primer in DNA ligation/amplification. The β CAP73-His insert was then digested with KpnI
35 and XbaI restriction endonucleases and ligated into the pcDNA3 vector. The construct was then re-sequenced to assess whether PCR amplification had generated mutations.

GFP- β CAP73 domains

Green fluorescent protein (GFP)- β CAP73 domain constructs were made in the same manner as the GST- β CAP73 domain constructs (see above), except that different primers were used in order to generate the 5' EcoRI and 3' BamHI restriction endonuclease sites (underlined) for in-frame ligation into pEGFP-C1 (Clontech). The following primer sets were used: GFP- β CAP73-N) forward, 5'GGAATTCAGTGGAAAGAGAATATGAAAGA (SEQ ID NO:22), reverse, 5'GCGGATCCTCAATGTGAACATTC (SEQ ID NO:23); GFP- β CAP73-C) forward, 5'CATTGAGAATTCTTATGAAACAG (SEQ ID NO:24), reverse, 5'CGGGATCCAATTCTTATGAAACAGAAAGAG (SEQ ID NO:25). All constructs were re-sequenced to check for potential PCR-generated mutations.

Overexpression and cellular localization of full-length β CAP73-His and GFP- β CAP73 in pericytes

For transient overexpression, pericytes (PCs) were plated onto 8-well chamber slides (Beckton Dickinson) at 40% confluency and grown overnight at 37°C. 1 μ g of DNA (GFP- β CAP73-N, GFP- β CAP73-C, β CAP73-His, or vector controls) was transfected into each well using Effectene transfection reagent (Qiagen, Santa Clarita, CA), and the cells were incubated for 48 h at 37°C. The GFP- β CAP73 domains were visualized live on a Zeiss IM-35 fluorescence microscope using a 40X, water-immersion objective lens (NA 0.75; Zeiss). β CAP73-His transfectants were identified after fixation and permeabilization. The cells were fixed for 5 min at RT with 4% formaldehyde made in 1X DME, prior to three washes with PBS, 5 min per wash. After fixation and washing, the cells were permeabilized with a 0.1% Triton X-100 buffer (50 mM Hepes, pH 6.9, 40 mM Pipes, pH 7.2, 75 mM KCl, 0.1 mM EGTA, 1 mM MgCl₂, 0.1% Triton-X 100) for 90 s at RT, followed by three PBS washes, 5 min per wash. After blocking the cells with 2.5 mg/mL BSA for 1 h at RT, the cells were probed with a 1:500 dilution of INDIA probe nickel detection (Pierce, Rockford, IL), followed by incubation with 1 μ g/mL rabbit anti-HRP antibody (Polysciences, Inc., Warrington, PA) and then 1 μ g/mL FITC-labeled, anti-rabbit antibody. The cells were visualized on a Zeiss IM-35 fluorescence microscope equipped with a 63X planapochromat oil immersion objective lens (Zeiss).

Example 4: Expression of Recombinant bcap73 Protein in COS cells

To express the β CAP 73 gene in COS cells, the pcDNA/Amp vector by Invitrogen Corporation (San Diego, CA) is used. This vector contains an SV40 origin of replication, an ampicillin resistance gene, an *E. coli* replication origin, a CMV promoter followed by a polylinker region, and an SV40 intron and polyadenylation site. A DNA fragment encoding the entire β CAP 73 protein and an HA tag (Wilson *et al.* (1984) *Cell* 37:767) or a FLAG tag fused in-frame to its 3' end of the fragment is cloned into the polylinker region of the vector,

thereby placing the expression of the recombinant protein under the control of the CMV promoter.

To construct the plasmid, the β CAP 73 DNA sequence is amplified by PCR using two primers. The 5' primer contains the restriction site of interest followed by approximately twenty nucleotides of the β CAP 73 coding sequence starting from the initiation codon; the 3' end sequence contains complementary sequences to the other restriction site of interest, a translation stop codon, the HA tag or FLAG tag and the last 20 nucleotides of the β CAP 73 coding sequence. The PCR amplified fragment and the pCDNA/Amp vector are digested with the appropriate restriction enzymes and the vector is dephosphorylated using the CIAP enzyme (New England Biolabs, Beverly, MA). Preferably the two restriction sites chosen are different so that the β CAP 73 gene is inserted in the correct orientation. The ligation mixture is transformed into *E. coli* cells (strains HB101, DH5 α , SURE, available from Stratagene Cloning Systems, La Jolla, CA, can be used), the transformed culture is plated on ampicillin media plates, and resistant colonies are selected. Plasmid DNA is isolated from transformants and examined by restriction analysis for the presence of the correct fragment.

COS cells are subsequently transfected with the β CAP 73-pcDNA/Amp plasmid DNA using the calcium phosphate or calcium chloride co-precipitation methods, DEAE-dextran-mediated transfection, lipofection, or electroporation. Other suitable methods for transfecting host cells can be found in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989. The expression of the β CAP 73 polypeptide is detected by radiolabelling (^{35}S -methionine or ^{35}S -cysteine available from NEN, Boston, MA, can be used) and immunoprecipitation (Harlow, E. and Lane, D. *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988) using an HA specific monoclonal antibody. Briefly, the cells are labeled for 8 hours with ^{35}S -methionine (or ^{35}S -cysteine). The culture media are then collected and the cells are lysed using detergents (RIPA buffer, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% DOC, 50 mM Tris, pH 7.5). Both the cell lysate and the culture media are precipitated with an HA specific monoclonal antibody. Precipitated polypeptides are then analyzed by SDS-PAGE.

Alternatively, DNA containing the β CAP73 coding sequence is cloned directly into the polylinker of the pCDNA/Amp vector using the appropriate restriction sites. The resulting plasmid is transfected into COS cells in the manner described above, and the expression of the β CAP73 polypeptide is detected by radiolabelling and immunoprecipitation using a β CAP73 specific monoclonal antibody.

Example 5: Expression of β CAP73 Protein in Calpastatin-Overexpressing Cells

Calpastatin-overexpressing cell lines were obtained from Dr. David Potter (Potter *et al.* 1998). To make lysates, cells from a confluent, 100 mm dish were rinsed three times with PBS at RT, scraped in 10 mL of PBS and transferred to a tube on ice. The cells were pelleted by centrifugation at 250 x g for 5 min at 4°C. After removing the supernatant, the cell pellet was resuspended in 0.5 mL of ice cold PBS plus protease inhibitors as previously described (Shuster *et al.*, 1996), prior to lysis by sonication on ice. The lysates were clarified by centrifugation at 20,000-x g for 20 min at 4°C, separated by SDS-PAGE, and transferred to nitrocellulose membrane. β CAP73 was detected using anti- β CAP73 mAb.

10 **Example 6: β CAP73 Expression in Cells Stimulated to Crawl**

When a confluent monolayer of ECs are disrupted by mechanical injury, cells crawl into the denuded zones in order to repopulate the wound space (Hooock *et al.*, 1991). We wanted to observe changes in the mRNA expression of β CAP73, since a regulator of actin assembly state would likely be expressed at different levels depending on the motile state of the cells. PolyA RNA isolated from populations of cells crawling for 30, 60, and 90 min following injury were compared to confluent, stationary cells. Northern blotting revealed that β CAP73 mRNA was, indeed, heavily regulated during the motile response to injury: While β CAP73 mRNA was high in confluent cells, it was just detectable at 30 min post-injury and gradually increased as the cells continued to crawl and infiltrate the wound space. The relative expression levels compared to confluent were 0.13 at 30 min, 0.25 at 60 min, and 0.38 at 90 min, where confluent = 1.

Example 7: β CAP73 Expression in Cells with Spreading Defects

Recently, a model system was developed to study the role of calpain in cell motility (Potter *et al.*, 1998). 3T3 cells were made to stably overexpress calpastatin, the naturally occurring inhibitor of calpain. These cells are smaller than their parent cells, produced fewer lamellae, and do not spread well. Importantly, these calpain-inhibited cells accumulate ezrin, a cellular calpain substrate (Yao *et al.*, 1993), and it appears that lack of ezrin cleavage is a primary cause of the spreading defects (Potter *et al.*, 1998; Shuster and Herman, 1995). Because ezrin, like β CAP73, associates with the barbed ends of β -actin filaments where it may also play a role in controlling actin dynamics, we asked whether β CAP73 protein levels were coordinately increased in these mutant cells. Immunoblotting showed that, like ezrin, β CAP73 was also up regulated in these motility-defective cells. β CAP73 was barely detectable in the parental 3T3 cells, which spread and migrate rapidly over fibronectin-coated growth substrate. But in the calpastatin overexpressing cells, β CAP73 levels were induced 10-fold. This increase in β CAP73 steady state protein level was not a part of general protein increase, since many cytoskeletal proteins did not change expression or did so minimally (Potter *et al.*, 1998). Of the ERM family members, only

ezrin is significantly induced, increasing 7-fold over parental levels (compared to 2-fold radixin and moesin; no change in talin).

Example 8: Overexpression of β CAP73 and β CAP73 Domains

5 Because changes in actin dynamics directly affects cell shape, it was hypothesized that overexpression of a regulator of β -actin dynamics, such as β CAP73, would alter spreading, motility, and morphology. Furthermore, due to the β -isoactin capping specificity of β CAP73, it was predicted that overexpression would primarily affect cortical membrane structures. Bovine retinal PCs overexpressing β CAP73-His were assessed for alterations in
10 cell morphology and localization of the recombinant protein 48 h after the start of transfection. In comparison to surrounding non-transfected cells, the β CAP73-His overexpressing cells were generally rounder and smaller. Using a probe against the histidine tag, the β CAP73-His fusion proteins were observed within novel surface protrusions that appeared to be apical plasma membrane-associated. Similarly,
15 overexpression of β CAP73 domains changed cell shape. Transient overexpression of GFP- β CAP73-N and GFP- β CAP73-C in PCs caused the cells to diminish in overall size, but maintain arborized processes. GFP control cells and surrounding untransfected cells remained flat and well spread, as observed by phase microscopy. In contrast to the condensed, membrane localization of the β CAP73-His, the GFP- β CAP73-N and the GFP-
20 β CAP73-C domains were not localized to a precise area within the cells, but remained diffuse.

Example 9: Effects of β CAP73 on β -Actin Expression

25 **Purification of actin isoforms**

Skeletal muscle β -actin was purified from chicken muscle acetone powder, prepared as previously described (Herman and Pollard, 1979; Spudich and Watt, 1971). Red blood cell (RBC) β -actin was purified from RBC acetone powder prepared as previously described (Puszkin et al., 1978; Shuster and Herman, 1995) with some modifications. Briefly, acetone
30 powder made from bovine RBCs was extracted twice in 15 mL G buffer per g of acetone powder, the first extraction for 5 h on ice at 4°C and the second extraction for 16 h on ice at 4°C. The extracts were then pooled and concentrated to one-tenth the starting volume before polymerization in 2 mM MgCl_2 and 100 mM KCl for 1 h at room temperature (RT). Following polymerization, the actin solution was brought up to 800 mM KCl and incubated
35 at 1 h RT. The polymerized actin was pelleted by centrifugation at 100,000-x g for 2 h at 4°C, de-polymerized by dialysis in G buffer, and then chromatographed on Sephadex G-150 (Sigma). Fractions were analyzed for purity by SDS-PAGE followed by staining with Coomassie Blue.

Pyrene labeling of actin isoforms

Isoactins were pyrene labeled based on the method of Kouyama and Mihashi (1981). Pyrene-iodoacetamide (Molecular Probes) was added to the labeling reaction at a molar ratio of 1:1.125 (actin:pyrene) in the following order and final concentrations: 40 μ M isoactin, 2 mM MgCl_2 , 45 μ M pyrene-iodoacetamide, 100 mM KCl. The reaction was polymerized/labeled for 1.5 h at RT in the dark. After centrifugation at 100,000-x g for 2 h at 10°C, pelleted pyrene-actin was depolymerized by dialysis in G buffer at 4°C, then clarified at 100,000-x g for 30 minutes (min) at 4°C before being frozen as aliquots in liquid nitrogen and stored at -80°C.

Barbed-end capping assays

The assays were performed as previously described (Weber et al., 1987) with modifications. 1 μ M (50% pyrene labeled) β - or α -actin in G buffer was seeded with 0.05-0.1 nM sheared F-actin seeds (isoactins polymerized at 30 μ M were sheared once through a 50 μ L Hamilton syringe just prior to addition to the reaction). The capping assays were performed as follows. The 1 μ M isoactin solution was pre-incubated with 0.2 mM MgCl_2 for 3 min at 25°C to allow for $\text{Ca}^{2+}/\text{Mg}^{2+}$ exchange. At time =0, isoactin seeds, various amounts of β CAP73, 2 mM MgCl_2 , and 100 mM KCl were added in rapid succession, mixed, and placed in a 0.5 cm^2 fluorimetry cuvette. Fluorescence intensity was detected on a Perkin-Elmer Luminescence Spectrometer LS 50B (excitation =365 nM, emission = 407 nM). The polymerization reactions were carried out at 25°C in 300 μ l reaction volumes.

Effects of β CAP73 on β -actin polymerization in vitro

In order to understand β CAP73 effects on the polymerization of β - and α -actins, GST- β CAP73 constructs were generated for bacterial expression.

The recombinant β CAP73 domains were tested for isoactin-specific capping of barbed-end in kinetic assays. To confine assembly to the barbed end, polymerization assays were carried out at 1 μ M actin. β -Actin polymerization at the barbed end was indeed inhibited by β CAP73. 1 μ M β CAP73-F inhibited β -actin assembly by 44% (Figure 5). Addition of 1 μ M β CAP73-C to β -actin was slightly inhibitory (26% inhibition), while β CAP73-N had minimal effect (5% inhibition). In contrast, none of the β CAP73 domains altered β -actin polymerization. Using 1 nM CapZ or gelsolin as controls for barbed-end inhibition, it was shown that both α - and β -actin assemblies were blocked indiscriminately.

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than

routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.